

Aus der Medizinischen Universitätsklinik und Poliklinik
Tübingen Abteilung Innere Medizin III
Schwerpunkt: Kardiologie und Kreislaufkrankungen

Macrophage migration inhibitory factor and gremlin-1 in
patients with coronary artery disease and diabetes: patterns
of expression and interaction

Inaugural-Dissertation
zur Erlangung des Doktorgrades
der Medizin

der Medizinischen Fakultät
der Eberhard Karls Universität
zu Tübingen

vorgelegt von

Karathanos, Athanasios

2018

Dekan: Professor Dr. I. B. Autenrieth
1. Berichterstatter: Professor Dr. T. Geisler
2. Berichterstatter: Professor Dr. H.P. Wendel

Tag der Disputation: 15.12.2017

LIST OF FIGURES.....	5
LIST OF TABLES.....	8
ABBREVIATIONS.....	9
1. INTRODUCTION	
1.1. CORONARY ARTERY DISEASE.....	12
1.2. DIABETES MELLITUS AND CARDIOVASCULAR DISEASE (CVD).....	14
1.3. ATHEROSCLEROSIS AND MANIFESTATIONS OF CAD.....	15
1.3.1. ENDOTHELIAL DYSFUNCTION, VASCULAR INFLAMMATION: THE VALNURABLE PLAQUE THEORY.....	17
1.3.2. MECHANISMS THAT CONTRIBUTE TO THE INCREMENTAL RISK FOR CAD IN DIABETICS.....	19
1.4. BIOMARKERS IN ACS.....	21
1.4.1. HIGH-SENSITIVITY C-REACTIVE PROTEIN.....	21
1.4.2. MACROPHAGE MIGRATION INHIBITORY FACTOR.....	23
1.4.3. GREMLIN-1.....	24
1.5. SCOPE OF THE INVESTIGATION.....	25
2. METHODS	
2.1. STUDY DESIGN.....	27
2.2. STUDY PATIENTS AND PROTOCOLS.....	27
2.3. CRITERIA FOR ACUTE MYOCARDIAL INFARCTION.....	28
2.4. DEFINITION OF DIABETES MELLITUS TYPE 2.....	29
2.5. WESTERN BLOT.....	30
2.6. FLUORESCENCE-ACTIVATED CELL SORTING (FACS).....	30
2.7. IMPEDANCE PLATELET AGGREGOMETRY.....	32
3. RESULTS	
3.1. MIF IS EXPRESSED IN HUMAN PLATELETS.....	33
3.1.1. DETECTION OF MIF BY WESTERN BLOT.....	33
3.1.2. IMMUNOFLUORESCENCE MEASUREMENTS OF MIF BY FACS.....	34
3.2. GREM1 IS EXPRESSED IN HUMAN PLATELETS.....	35
3.2.1. DETECTION OF GREM1 BY WESTERN BLOT.....	35
3.2.2. IMMUNOFLUORESCENCE MEASUREMENTS OF GREM1 BY FACS.....	36
3.3. STUDY SUBJECTS' CHARACTERISTICS.....	37
3.4. PLATELET MIF AND GREM1 EXPRESSION ARE INDEPENDENT OF PLATELET COUNT.....	44
3.5. PLATELETS STIMULATED WITH ADP PRODUCE DIFFERENT AMOUNTS OF MIF AND GREM1.....	44

3.6. THE LEVELS OF MIF EXPRESSED BY PLATELETS CORRELATES WITH THE EXPRESSION OF GREM1 IN THE SAME PATIENT.....	46
3.7. P-SELECTIN PLATELET EXPRESSION CORRELATES WITH MIF AND GREM1 EXPRESSION.....	46
3.8. PLATELET REACTIVITY AS MEASURED WITH MULTIPLATE® ANALYSER WAS INDEPENDENT FROM MIF AND GREM1 EXPRESSION	47
3.9. LEVELS OF MIF AND GREM1 EXPRESSION FROM PLATELETS CORRELATE WITH THE LEVELS OF GLYCOPROTEIN VI EXPRESSION FROM PLATELETS.....	48
3.10. LEVELS OF MIF AND GREM1 EXPRESSION FROM PLATELETS CORRELATE WITH THE LEVELS OF PAC-1 EXPRESSION FROM PLATELETS	50
3.11. LEVELS OF GREM1 EXPRESSION FROM PLATELETS AND PLASMA LEVELS CORRELATE WITH CaRDIAC NecrOSIS MARKER CREATININE KINASE	50
3.12. LEVELS OF GREM1 AND MIF EXPRESSION FROM PLATELETS CORRELATE WITH TROPONIN I.....	52
3.13. LEVELS OF SERUM CRP, MIF AND GREM1 EXPRESSION FROM PLATELETS ARE INCREASED IN DIABETICS.....	52
3.14. ONGOING THERAPY REGIMENT FOR DIABETES DID NOT CORRELATE WITH THE EXPRESSION OF MIF FROM PLATELETS.....	53
3.15. MIF EXPRESSION FROM PLATELETS CORRELATES WITH THE SUCCESS IN CONTROLLING GLUCOSE LEVELS IN CAD PATIENTS	54
3.16. GREM1 EXPRESSION IN PLATELETS CORRELATES WITH THE SUCCESS IN CONTROLLING GLUCOSE LEVELS IN CAD PATIENTS	55
3.17. MIF AND GREM1 PLATELET LEVELS ARE LOWER IN PATIENTS WITH IMPAIRED EJECTION FRACTION	56
3.18. MIF AND GREM1 PLATELET LEVELS ARE SIGNIFICANTLY LOWER IN ACS PATIENTS WITH IMPAIRED EJECTION FRACTION.....	57
3.19. THE CLINICAL PRESENTATION OF IHD CORRELATES WITH THE LEVELS OF MIF AND GREM1 EXPRESSED BY PLATELETS.....	58
3.20. PLASMA LEVELS OF GREM1 CORRELATE WITH PLASMA CRP LEVELS	60
3.21. PLASMA LEVELS OF GREM1 AND MIF WERE INDEPENDENT OF WHITE BLOOD CELL COUNT	60
3.22. PLASMA LEVELS OF GREM1 CORRELATED WITH RENAL FUNCTION MARKER.....	60
3.23. PLATELET BOUND GREM1 AND MIF EXPRESSION IS INDEPENDENT OF CONCOMITANT MEDICATION	61
4. DISCUSSION	

4.1. MIF IN CORONARY ARTERY DISEASE AND TYPE 2 DIABETES MELLITUS	62
4.2. GREMLIN-1 AS AN ENDOGENOUS ANTAGONIST OF MIF AND ITS ROLE IN ATHEROSCLEROSIS	64
4.3. EXPRESSION OF GREM1 AND MIF IN OUR GROUP OF PATIENTS WITH IHD	65

LIST OF FIGURES

FIGURE 1.1: GLYCAEMIC CONTINUUM AND CARDIOVASCULAR DISEASE

FIGURE 1.2: DEVELOPMENT OF ATHEROSCLEROSIS AND POSSIBLE PROGRESSION TO THROMBOSIS AND CORRESPONDING CLINICAL EVENTS

FIGURE 1.3: INTERACTION OF THE PATHOPHYSIOLOGICAL MECHANISMS IN DIABETES AND THE RESULTING ATHEROTHROMBOTIC RISK.

FIGURE 3.1: QUALITATIVE STUDY OF MIF EXPRESSION IN PLATELETS

FIGURE 3.2: FLOW CYTOMETRIC ANALYSIS OF THE EXPRESSION OF MIF

FIGURE 3.3: QUALITATIVE EXPRESSION OF GREM1 IN PLATELETS

FIGURE 3.4: FLOW CYTOMETRIC ANALYSIS OF THE EXPRESSION OF GREM1

FIGURE 3.5: SCATTERPLOT PRESENTING THE CORRELATION OF THE MEAN VALUES OF MFI OF MIF (ABOVE) AND GREM1 (BELOW) WITH THE PLATELET COUNT IN OUR COHORT.

FIGURE 3.6: SCATTERPLOTS PRESENTING THE CORRELATION OF THE MEAN VALUES OF MFI OF MIF WITH MIF IN PLATELETS STIMULATED WITH ADP (ABOVE) AND GREM1 IN RESTING PLATELETS AND GREM1 IN PLATELETS STIMULATED WITH ADP.

FIGURE 3.7: SCATTERPLOT PRESENTING THE CORRELATION OF THE MEAN VALUES OF MFI OF MIF AND GREM1.

FIGURE 3.8: SCATTERPLOTS PRESENTING THE CORRELATION OF THE MEAN VALUES OF MFI OF MIF AND GREM1 WITH MEAN VALUES OF P-SELECTIN.

FIGURE 3.9: SCATTERPLOTS PRESENTING THE CORRELATION OF THE MEAN VALUES OF MFI OF MIF AND GREM1 WITH VALUES OF PLATELET REACTIVITY.

FIGURE 3.10: SCATTERPLOTS PRESENTING THE CORRELATION OF THE MEAN VALUES OF MFI OF MIF AND GREM1 WITH MEAN VALUES OF MFI OF SDF-1.

FIGURE 3.11: SCATTERPLOT PRESENTING THE CORRELATION OF THE VALUES OF PLASMA LEVELS OF GREM1 AND MEAN MFI VALUES OF PLATELET GREM1 WITH CREATININE KINASE.

FIGURE 3.12: SCATTERPLOTS PRESENTING THE CORRELATION OF THE MEAN MFI VALUES OF MIF AND GREM1 TO TROPONIN.

FIGURE 3.13: CLUSTERED BAR PRESENTING THE MEAN VALUES OF CRP, MIF AND GREM1 IN CORRELATION WITH DIABETIC STATUS OF THE SUBJECTS.

FIGURE 3.14: SCATTERPLOT PRESENTING THE CORRELATION OF THE MEAN VALUES OF HBA1C AND MFI FOR MIF FROM RESTED PLATELETS AND MIF FROM ACTIVATED ONES.

FIGURE 3.15: BOXPLOTS DISPLAYING THE EXPRESSION OF GREM1 FROM RESTING AND STIMULATED PLATELETS OF DIABETICS ACCORDING TO THEIR GLUCOSE CONTROL.

FIGURE 3.16: BOX BLOTS PRESENTING THE CORRELATION OF MIF IN RESTING AND ACTIVATED PLATELETS WITH THE EJECTION FRACTION.

FIGURE 3.17: CLUSTERED ERROR BARS REPRESENTING THE MEAN MFI FOR MIF AND GREM1 DEPENDING ON THE CLINICAL PRESENTATION OF THE PATIENTS.

FIGURE 3.18: BOXPLOTS PRESENTING THE PLASMA LEVELS OF MIF AND GREM1 IN THE DIFFERENT STRATA OF IHD.

FIGURE 3.19: BOXPLOT PRESENTING THE PLASMA LEVELS OF GREM1 IN RELATION WITH THE CRP PLASMA LEVELS.

FIGURE 3.20: CLUSTERED BAR GRAPHS PRESENTING THE RELATION BETWEEN MIF AND GREM1 EXPRESSION FROM PLATELETS IN PATIENTS STRATIFIED ACCORDING TO TREATMENT WITH ACETYLSALICYLIC ACID AND VITAMIN K ANTAGONISTS.

FIGURE 3.21: CLUSTERED BAR GRAPHS PRESENTING THE RELATION BETWEEN MIF AND GREM1 EXPRESSION FROM PLATELETS IN PATIENTS UNDER TREATMENT WITH ADENOSINE DIPHOSPHATE RECEPTOR INHIBITORS.

FIGURE 3.22: CLUSTERED BAR GRAPHS PRESENTING THE RELATION BETWEEN PLATELET MIF EXPRESSION AND TREATMENT WITH STATINS.

FIGURE 3.23: CLUSTERED BAR GRAPHS PRESENTING THE RELATION BETWEEN PLATELET MIF EXPRESSION AND GREM1 EXPRESSION AND ADEQUATE CONTROL OF LDL-CHOLESTERIN.

LIST OF TABLES

TABLE 2.1: INCLUSION AND EXCLUSION CRITERIA FOR THE STUDY.

TABLE 2.2: MAJOR DIAGNOSTIC CRITERIA FOR DIABETES AND
PREDIABETIC OR AT-RISK STATES.

TABLE 2.3: REAGENTS USED IN IMPEDANCE PLATELET
AGGREGOMETRY.

TABLE 3.1. BASELINE CHARACTERISTICS OF THE PATIENT COHORT

TABLE 3.2. BASELINE CHARACTERISTICS ACCORDING TO DIABETES
STATUS

ABBREVIATIONS

Ab	Antibody
ACS	Acute Coronary Syndrome
ADA	American Diabetes Association
ADP	Adenosine Diphosphate
AMPK	AMP-Activated Protein Kinase
ATP	Adenosine Triphosphate
AUC	Area Under the Curve
BMI	Body-Mass Index
BMPs	Bone Morphogenetic Proteins
BSA	Bovine Serum Albumin
CABG	Coronary Artery Bypass Surgery
CAD	Coronary Artery Disease
CD42a	Glycoprotein IX or Cluster of Differentiation 42a
CD62P	P-Selectin
CHD	Coronary Heart Disease
CRP	C-Reactive Protein
CURE	Clopidogrel in Unstable Angina to Prevent Recurrent Events
CV	Cardiovascular
CVDs	Cardiovascular Diseases
CXCR2	Chemokine (C-X-C Motif) Receptor 2
CXCR4	Chemokine (C-X-C Motif) Receptor 4
DALY	Disability-Adjusted Life Year
EASD	European Association for the Study of Diabetes
EDTA	Ethylenediaminetetraacetic Acid
EF	Ejection Fraction
ELISA	Enzyme-Linked Immunosorbent Assay
FACS	Fluorescence-Activated Cell Sorting

FFA	Free Fatty Acid
FITC	Fluorescein Isothiocyanate
GIF	Glycosylation-Inhibiting Factor
GPVI	Platelet Glycoprotein VI
GREM1	Gremlin-1
HbA1c	Glycated Hemoglobin A1C
HDL	High-Density Lipoprotein
HPR	High Platelet Reactivity
hsCRP	High Sensitivity C-Reactive Protein
IGF	Impaired Fasting Glucose
IGT	Impaired Glucose Tolerance
IHD	Ischemic Heart Disease
IL-6	Interleukin-6
IQR	Interquartile Range
IVUS	Intravascular Ultrasound
LDL-C	Low-Density Lipoprotein Cholesterol
MACE	Major Adverse Cardiac Events
MFI	Median Fluorescence Intensity
MFI	Median Fluorescence Intensity
MI	Myocardial Infarction
MIF	Macrophage Migration Inhibitory Factor
MMIF	Macrophage Migration Inhibitory Factor
MMPs	Matrix Metalloproteinases
mRNA	Messenger RNA
NSTEMI	Non-ST Segment Elevation Myocardial Infarction
OGTT	Oral Glucose Tolerance Test
OxLDL	Oxidized Low-Density Lipoprotein
P2RY12	Inergic Receptor P2Y, G-Protein Coupled, 12
PAC-1	First Procaspase Activating Compound
PAMPs	Pathogen-Associated Molecular Patterns

PBS	Phosphate Buffered Saline
PCI	Percutaneous Coronary Intervention
PFA	Paraformaldehyde
PG	Plasma Glucose
PRM	Pattern Recognition Molecule
PVDF	Polyvinylidene Difluoride
ROS	Reactive Oxygen Species
SCAD	Stable Coronary Artery Disease
SD	Standard Deviation
SDF-1	Stromal Cell-Derived Factor 1
SDS-PAGE	SDS-Polyacrylamide Gel Electrophoresis
SMCs	Smooth Muscle Cells
SR-B	Scavenger Receptor B
STEMI	ST Segment Elevation Myocardial Infarction
T2DM	Type 2 Diabetes Mellitus
TGF- β	Transforming Growth Factor Beta
TNF- α	Tissue Necrosis Factor-alpha
UA	Unstable Angina
URL	Upper Reference Limit
VCAM-1	Vascular Cell Adhesion Molecule-1
VEGFR-2	Vascular Endothelial Growth Factor Receptor 2
VLDL	Very Low-Density Lipoprotein
WHO	World Health Organization

1. INTRODUCTION

1.1. CORONARY ARTERY DISEASE

Coronary artery disease (CAD) also called coronary heart disease (CHD) or ischemic heart disease (IHD) is caused by the obstruction of one or more coronary arteries resulting from the accumulation of atheromatous plaques within the walls of the coronary arteries. It is the leading cause of death worldwide accounting for 7.025 million deaths yearly or 12.9 per cent of total deaths (116) and the mortality is projected to rise to 7.594 million deaths or 13.2% of deaths by 2015 and 9.245 million deaths or 13.2% by 2030 (117). In Europe ischemic heart disease is the leading cause of death with 2.245 million deaths or 24.8% of all deaths in 2011 (116). Nevertheless, ischemic heart disease does not consist a problem only when it has a fatal outcome. It is also one of the leading causes of burden of disease in the world. IHD accounted for 159.659.000 disability-adjusted life years (DALYs) or 5.8% of total DALYs in 2011. This data puts IHD on the 2nd place of leading causes of morbidity after lower respiratory infections with increasing tendency in the last decade (114).

The manifestation of CAD was first clinically described based on the angina symptoms classified by Herberden in 1772 (156). Since then there has been extended research focused on the pathophysiological mechanisms that lead to CAD. The clinical manifestations of CAD include silent ischemia, stable angina pectoris, unstable angina pectoris (UA), myocardial infarction (MI), heart failure, and sudden cardiac death.

Traditional risk factors for CAD include smoking (102, 145), obesity (121), dyslipidemia, arterial hypertension, diabetes and chronic kidney disease. Thus lifestyle modifications are suggested in CAD patients such as smoking cessation that is associated with a 36% mortality reduction in the post MI phase (37), adoption of a healthy diet such as “Mediterranean” diet (52), weight management (121) and physical activity.

At the same time pharmacological management plays an important role in relief from symptoms and prevention of cardiovascular events. For the symptomatic treatment of angina short acting nitrates, β -blockers or calcium channel blockers, ranolazin and ivabradine are indicated. For prevention of thromboischemic events a low-dose aspirin daily is recommended in all CAD patients with clopidogrel as an alternative in case of aspirin intolerance. Statins are recommended for all CAD patients and angiotensin converting enzyme inhibitors or Angiotensin II receptor blockers are recommended in the presence of comorbidities such as heart failure, diabetes or hypertension (143).

When evaluating a patient with chronic coronary artery disease, doctors must choose their strategy between catheterization with revascularization, if feasible, combined with drug therapy or initial medical management with revascularization only if drug therapy fails. Although the superiority of coronary revascularization in relieving angina has been a consistent finding in many trials, only patients with high-risk profiles have been shown to benefit by reducing rates of subsequent myocardial infarction and (20, 44, 80, 162). Diabetics though present a high-risk group even when only mild symptoms are manifest. But trials in this group have also been controversial regarding major adverse cardiac events (MACE). The largest trial in the diabetic population showed that either therapeutic decision is correct in the setting of stable CAD (40). Latest trials have focused on which of the invasive options are most beneficial for diabetics with multivessel coronary artery disease, without reaching a unanimous verdict (55, 151).

In patients with ACS, guidelines are clearer with an invasive treatment recommended for all patients without contraindications for revascularization. In STEMI patients the revascularization should be prompt, whereas in UA and NSTEMI patients without recurrent ischemia in the first 24 hours the invasive risk stratification can be reserved for a later time point, depending on their cumulative risk (e.g. calculated by the GRACE-score) between 2 and 72 hours (72, 143, 144).

1.2. DIABETES MELLITUS AND CARDIOVASCULAR DISEASE (CVD)

Data from multiple epidemiological studies show that diabetes mellitus type 2 (T2DM) is a major risk factor contributing to the development of all manifestations of cardiovascular disease, including fatal and non-fatal myocardial infarction and heart failure (5). Recent data support an increasing burden of cardiovascular disease attributable to diabetes mellitus (61). Along with the globally increasing prevalence of obesity and the aging population, the incidence and prevalence of T2DM is anticipated to rise. From the year 2000 to 2030 increase of the prevalence of T2DM is projected to 100%, with those older than 65 years of age contributing the biggest share (155). CVD and cardiovascular events are major contributors to morbidity and mortality of diabetics, with estimations holding CVD responsible for at least 50% of all deaths in T2DM patients (15, 24, 38, 69, 115, 124).

In the Norfolk cohort of European Prospective Investigation Into Cancer and Nutrition (EPIC-Norfolk) trial an increase of 1% in glycated hemoglobin (HbA1c) was associated with a 40% increase in CVD mortality in T2DM patients and with a 28% increase in risk of death independent of age, blood pressure, serum cholesterol, body mass index, and cigarette smoking habit (87). A meta-analysis of almost 700.000 subjects from 102 different prospective studies reported that diabetics presented with a near 2-fold increase in CVD risk, independent from other known CVD risk factors (50). Intensive glycemic control and its impact on CV outcomes has been a controversial subject for at least 2 decades (67). Therefore it is clear that metabolic control is essential in treating diabetics with CVD.

A goal HbA1c of less than 7.0% has been proposed by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) for most of T2DM patients (81). The same position paper advises towards less stringent goals for patients with a history of severe hypoglycemia, limited life expectancy, advanced microvascular or macrovascular disease, or

those with long-standing diabetes (13). It has also been suggested that insulin may be atherogenic in a dose dependent fashion (42).

CVD risk in T2DM patients most likely owes a multifactorial etiology. In T2DM patients there is often a clustering of additional CV risk factors closely associated with insulin resistance, including hypertension and central obesity (2, 41, 112).




Figure 1.1 Glycemic continuum and cardiovascular disease.

Diabetes mellitus type 2 is a state of combined IR, compensatory hyperinsulinemia and elevated PG, which lead to a higher cardiovascular risk and rapid development of macrovascular disease prior to diagnosis of diabetes (13).

1.3. ATHEROSCLEROSIS AND MANIFESTATIONS OF CAD

Epicardial coronary arteries are a major site of clinically relevant atherosclerotic disease (91, 129). Atherosclerosis is a chronic, systemic, lipid-associated, immuno-inflammatory disease of the medium and large-sized arteries resulting in plaque development. Plaques are principally formed at predilection sites that

are characterized by high endothelial stress (32). Atherosclerosis begins with our birth and the lesions develop over the course of our life, one of the longest incubation periods among human diseases. Despite the chronic character of the disease, its most dangerous effects occur suddenly. CAD includes two pathophysiological pathways that determine the clinical manifestations of the disease. One chronic, non-reversible process of progressive stenosis of the lumen of the coronary arteries and a very dynamic but potentially reversible process that leads to a hemodynamically significant occlusion of the coronary artery (131).

Most plaques stay asymptomatic, some become obstructive leading to stable angina and a few are prone to thrombosis and disruption (vulnerable). When the progression of atherosclerosis has led to a high-grade stenosis, a platelet thrombus can occlude the vessel completely and cause ST-segment elevation myocardial infarction. When only incomplete or transient obstruction of flow occurs, the result is an acute coronary syndrome without persisting ST-segment elevation. In the complex process of plaque vulnerability and disruption inflammation plays an important pathophysiological role. Rarely, ACS may have a non-atherosclerotic etiology, e.g. thoracic trauma, dissection of arteries, thromboembolism, cocaine abuse or iatrogenic.




Figure 1.2: Development of atherosclerosis and possible progression to thrombosis and corresponding clinical events (131).

1.3.1. ENDOTHELIAL DYSFUNCTION, VASCULAR INFLAMMATION: THE VALNURABLE PLAQUE THEORY

According to the prevalent theory sudden and unpredictable changes in symptoms of atherosclerosis appear to be associated with plaque disruption. Genesis of ACS is the plaque rupture and not every plaque poses the same

danger of rupture. Patients with unstable angina or NSTEMI often enough have multiple plaques vulnerable to disruption (6, 68).

Pathological studies in humans showed that thrombotic coronary occlusion after rupture of a lipid-rich atheroma seems to be the trigger for myocardial infarction in 73% of the cases (54, 56, 57).

One of the seminal clinical studies outlining this is the collaborating PROSPECT Trial, in which Stone and colleagues investigated 697 patients undergoing elective PCI and systematic interventional imaging of the entire coronary artery tree using intravascular ultrasound (IVUS) to try to characterize the risk that individual lesion characteristics at baseline conferred regarding the recurrence of coronary events. This study identified three characteristics associated with plaque vulnerability:

1. High plaque burden >70% (hazard ratio (HR) 5.03)
2. Small minimal lumen area (<4 mm², HR 3.21)
3. Classification as a thin-cap fibroatheroma (HR 3.35) (139)

The notion that cells mostly associated with the inflammatory response play an important role in the pathogenesis of ACS found fertile ground in the scientific community (74, 92). Currently it's a common ground that the activation of inflammatory cells in the culprit lesion triggers the coronary plaque instability (73, 92). With imaging techniques available today investigation of arterial wall inflammation is indirectly possible e.g. by using FDG-PET (60).

The dysfunctional endothelium cannot properly regulate the recruitment of leukocytes. Macrophage foam cells serve as lipid reserve and also induce decreased production of nitric oxide, aggravate the endothelial dysfunction (163) and lead to thickening of the intima media (59). They also serve as a source of pro-inflammatory mediators, such as cytokines and chemokines,

reactive oxygen intermediates or platelet activating factor that lead to a prolonged inflammatory activation of the endothelium (66).

This type of antigen-stimulation independent amplified inflammatory response is described as innate immunity. Proliferation of smooth muscle cells (SMCs) furthers promotes atherosclerosis. Extracellular matrix makes up most of the volume of an atherosclerotic plaque in advanced stages. The imbalance in its production lies with the disrupted breakdown, which is catalyzed in part by matrix metalloproteinases (MMPs).

The fibrous cap is a dynamic structure undergoing active remodeling. With its high concentration of type I collagen it can resist high amounts of stress. The collagen de novo synthesis is modulated by growth factors and supported by degradation through proteases produced from activated macrophages. The local apoptosis of SMCs on the cap tissue can also contribute to rupture (142).

The lipid-rich core of the fibroatheroma when exposed after plaque rupture is highly thrombogenic and the thrombosis can lead to total or subtotal occlusion of the artery that cannot be compensated for through positive remodeling. This thrombus can fragment into smaller pieces, creating emboli that may cause necrosis in the area of the myocardium supplied by the culprit vessel (39, 53).

1.3.2. MECHANISMS THAT CONTRIBUTE TO THE INCREMENTAL RISK FOR CAD IN DIABETICS

The atheroma in type 2 diabetics is more prone to inflammation, thrombosis and has a higher lipid concentration than that of non-diabetics. T2DM patients are obese (78) and adipose tissue at a hyperglycemic state intensively accumulates macrophages, that form foam cells and promote atherosclerosis through oxidized low-lipoprotein (LDL) scavenger receptor B (SR-B) and releases substances that further impair insulin sensitivity (128). At the same time

endothelial dysfunction and vascular remodeling is promoted involving overproduction of reactive oxygen species (ROS) (13, 36).


The free fatty acids (FFA) induce increased production of very low-density lipoprotein (VLDL), which is more susceptible to oxidative stress (119, 164). At the same time the function of high-density lipoprotein (HDL) as protective factor is lost in diabetics (8, 62, 90).

T2DM is a prothrombotic state with hypofibrinolytic abnormalities (70) and hyper-reactive, dysfunctional platelets. Hyperglycemia-induced up-regulation of platelet glycoproteins (Ib and IIb/IIIa), P-selectin and enhanced P2Y₁₂ signaling are associated with the atherothrombotic risk in diabetics. Furthermore, the cardiovascular risk burden in T2DM is not diminished by intensive glycemic control and mechanism-based therapeutic strategies are needed such as inhibition of key-enzymes involved in protein-production and activation of pathways. There is also need for biomarkers aiding in early detection of CAD in asymptomatic patients and prediction of CV risk (13).

Figure 1.3: Interaction of the pathophysiological mechanisms in diabetes and the resulting atherothrombotic risk.

More than 90% of people with T2DM are obese and the release of free fatty acids (FFAs) and cytokines from adipose tissue directly impairs insulin sensitivity. The picture presents the interaction of the pathophysiological mechanisms in diabetes and the resulting atherothrombotic risk. Connecting arrows depict the mediators of such interactions.

AGE = advanced glycated-products; FFA = free fatty acids; GLUT-4 = glucose transporter 4; HDL-C = high-density lipoprotein cholesterol; LDL = low-density lipoprotein particles; NO = nitric oxide; PAI-1 = plasminogen activator inhibitor-1; PKC = protein kinase C; PPAR γ = peroxisome proliferator-activated receptor γ ; PI3K = phosphatidylinositide 3-kinase; RAGE = AGE receptor; ROS = reactive oxygen species; SR-B = scavenger receptor B; tPA = tissue plasminogen activator (13).



1.4. BIOMARKERS IN ACS

1.4.1. HIGH-SENSITIVITY C-REACTIVE PROTEIN

The acute-phase reactant CRP has emerged as a predictor for long-term events in ACS (125). CRP belongs to the superfamily of pentraxins and more specifically to the classic short pentraxins. It is a secreted endogenous PRM (pattern recognition molecule) and is synthesized by the liver (64). Limited number of germline-encoded PRMs are used by the innate immune system to detect conserved molecular structures known as pathogen-associated

molecular patterns (PAMPs) exposed on pathogens but absent from healthy host cells (82, 120, 123).

In humans, CRP is a major acute-phase plasma protein, in which the serum concentration can rapidly increase in response to infection or tissue injury. It is the principal downstream mediator of the acute phase response and is primarily derived via IL-6- dependent hepatic biosynthesis. During the acute phase response, levels of CRP will increase within 2 hours of acute insult, reaching a peak at 48 hours and start declining relatively rapidly with a half-life of 18 hours.

CRP levels can increase as a response to a wide variety of biological insults, infections, autoimmune inflammatory conditions or malignant processes. While CRP has multiple pro-inflammatory and proatherogenic properties, recent studies, one using a mendelian randomization approach (30) and a large genomics study (49), both reached the conclusion that C-reactive protein does not seem to be the cause of coronary heart disease, although it is a risk marker for it (49, 146). Various medications have been proved to reduce serum CRP levels, e.g. aspirin and clopidogrel or statins and that in turn reduce the incidence of major cardiovascular events (83, 127).

After Liuzzo's et al. first report on the prognostic role of CRP in acute coronary syndromes (94), several trials and meta-analysis have put that finding in clinical context (49) and now serum CRP levels are used in scores to determine one-year mortality and the 10-year cardiovascular risk (122, 126, 157). The American Heart Association and the American College of Cardiology gave a recommendation for testing of CRP in asymptomatic intermediate-risk men 50 years of age or younger or women 60 years of age or younger as a tool for CV risk assessment (Level of Evidence: B) (71). Elevation of CRP-levels is not only a predictor for CV-events, but also for the onset of T2DM. This might be because CRP correlates with characteristics of the metabolic syndrome, including insulin sensitivity, endothelial dysfunction, and hypofibrinolysis, as noted earlier.

Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study showed no association of CRP levels with P2Y₁₂ inhibition and diminished levels of CRP 30days after the event (161). The concept of use of statins to reduce the CV-risk in patients with elevated hs-CRP independent from LDL-Cholesterol levels has been confirmed in the A-to-Z clinical trial (107) and the JUPITER trial (127).

1.4.2. MACROPHAGE MIGRATION INHIBITORY FACTOR

Macrophage migration inhibitory factor (MIF or MMIF) also known as glycosylation-inhibiting factor (GIF), L-dopachromeisomerase/tautomerase, or phenylpyruvatetautomerase is a very pleiotropic and widely studied inflammatory cytokine, an evolutionarily highly conserved molecule with an almost ubiquitous expression pattern and an extensive regulatory activity in humans. MIF was first isolated back in the 60's, as a protein from the supernatant of activated lymphocytes, however little was then known about its role. More light in its function was shed after the introduction of molecular biology. More specifically, MIF was categorized as a chemokine like factor in humans (43).

MIF is expressed on the endothelium and macrophages and in humans it is involved in the innate immune response to bacterial pathogens and its expression at sites of inflammation suggests a role as mediator in regulating the function of macrophages in host defense. MIF counteracts the anti-inflammatory activity of glucocorticoids. Serum levels of MIF are elevated in patients with severe sepsis or septic shock and high levels of MIF are correlated with poor survival and drugs that inhibit tautomerase activity attenuate the risk of death due to sepsis (17, 18, 26, 27, 47, 51, 89, 104, 154). Data is widely available on the functions of this versatile molecule including its role in glomerulonephritis (159) and arthritis (16).

Regarding cardiovascular diseases, the expression and activity of MIF was recorded in the onset of atherogenesis and advanced lesions of hypercholesterolemic rabbits and humans (93). MIF is an inflammatory cytokine with a chemokine-like function, promoting leukocyte recruitment, adhesion and atherosclerotic lesion formation via the chemokine receptors CXCR2 und CXCR4 (23). It has also been shown that MIF deficiency considerably reduces atherogenesis in LDLr^{-/-} (118), but no data is available on serum levels of MIF in CVD. Despite its wide tissue distribution, the secretion of MIF is tightly regulated, with triggers such as hypoxia/ischemia or oxidized low-density lipoprotein (9). Schmeisser et al. showed that MIF is expressed by advanced plaques and mainly in areas of enhanced instability (132); nevertheless the current studies are in dispute regarding how MIF affects the plaque size and stability of the vulnerable plaque (22, 134).

Latest studies have shown a correlation of levels of MIF with cardiac dysfunction in diabetic patients (97, 160). In a known background of elevated MIF levels in diabetics and the correlation of MIF with the progression of glucose resistance to diabetes (88, 150, 152) the MONICA/KORA Augsburg Case-Cohort Study tried to include multiple inflammation-related biomarkers into a basic risk assessment model for cardiovascular events in type 2 diabetics (75).

Pilot studies of our group demonstrated correlation of MIF levels with established inflammatory markers, the extent of cardiac necrosis marker release after PCI and ACS (110).

1.4.3. GREMLIN-1

Gremlin-1 is a secreted, highly conserved glycoprotein with an atomic mass of 20.7 kDa and a structure shared by members of the TGF- β superfamily and Vascular Endothelial Growth Factors (106, 148, 149). Gremlin-1 plays a part

during lung, limb, urethra and kidney formation and neural crest cell differentiation through regulation of BMPs (33, 96, 103, 135, 140). Through its interaction with Slit proteins Gremlin-1 functions as an inhibitor of monocyte chemotaxis and through binding of VEGFR-2 acts as a proangiogenic agonist with a role in vascular development, angiogenesis-dependent diseases, and tumor neovascularization (106).

Gremlin-1 is expressed in endothelial cells that are exposed to disturbed flow in mice aortas as well as in human coronary arteries (31, 45). An up-regulation of Gremlin-1 in pericytes in response to elevated glucose levels was reported, suggesting a role in diabetic retinopathy (85). Additionally, a role in tubulointerstitial fibrosis in diabetic nephropathy has been suggested (46).

In studies of our group we could demonstrate that Gremlin-1 regulates foam cell formation in vitro, is an endogenous antagonist of MIF and binds with high affinity to MIF. Administration of a dimeric recombinant fusion protein mGremlin-1-Fc reduced the content of macrophages in atherosclerotic plaques, and limits atheroprogession and lesion instability (109). One can speculate that GREM1 plays a pivotal role in proliferation of atherosclerotic lesions and plaque vulnerability and consequently instability.

Pilot studies of our group in patients with ACS suggest a potential role of Grem1/MIF ratio to indicate acuity of CAD and the grade of plaque stability (108).

1.5. SCOPE OF THE INVESTIGATION

In this study we aimed to evaluate the expression of MIF and GREM1 in patients with symptomatic IHD with major focus in diabetics with CAD. Following research questions were pursued:

1. Are MIF and GREM1 expressed from human platelets, and if yes at what degree?
2. Is the expression of MIF and GREM1 from human platelets dependent from platelet count, platelet activation or platelet aggregation?
3. Is there a correlation between MIF and GREM1 levels in human platelets
4. Do patients with stable ischemic heart disease express MIF and GREM1 at the same degree as patients with acute coronary syndromes?
5. Do diabetics with symptomatic ischemic heart disease have the same MIF and GREM1 platelet levels compared to non-diabetics?

2. METHODS

2.1. STUDY DESIGN

The study was conducted at the Universitätsklinikum Tübingen, Medizinische Universitätsklinik, Department für Innere Medizin III, Kardiologie und Kreislaufkrankungen. The institutional review board approved the study (270/2011BO1).

2.2. STUDY PATIENTS AND PROTOCOLS

Patients with stable CAD or acute coronary syndromes were enrolled at the time of percutaneous coronary intervention (PCI). The inclusion and exclusion criteria are as listed in Table 2.1. ACS Patients that did not undergo an intervention, either because of ACS without significant coronary stenosis or because they were referred for coronary artery bypass surgery (CABG) or because they were considered too frail/critical for intervention were not included in this study. All patients provided written informed consent. The study was approved by the institution ethics committee (270/2011BO1) and complies with the declaration of Helsinki and the good clinical practice guidelines (1, 3, 4).

Table 2.1: Inclusion and exclusion criteria in our study

Clinical inclusion criteria

1. Age ≥ 18 years
2. Symptomatic CAD undergoing PCI
3. Patient provides written, informed consent.

Clinical exclusion criteria

1. Pregnant or nursing patients

Angiographic inclusion criteria

1. Lesions in at least 1 epicardial coronary artery requiring reperfusion therapy.
2. Successful PCI of at least one lesion.

Levels of serum creatinine, fasting lipids, glucose, glycated hemoglobin, and C-reactive protein were measured at baseline. Blood was collected in EDTA tubes at the time of angiography, centrifuged at room temperature (1500xg) for 15 min and the supernatants were stored as EDTA-plasma at -80°C for the ELISA. At the same time citrate phosphate dextrose adenine (CPDA)-tubes were collected for the fluorescence-activated cell sorting (FACS). 1.5 mL blood was collected in hirudin tubes for Multiplate measurements of agonist induced platelet aggregation.

2.3. CRITERIA FOR ACUTE MYOCARDIAL INFARCTION

Acute myocardial infarction was defined according to the third universal definition (147). Detection of a rise and/or fall of cardiac troponin with at least one value above the 99th percentile URL and with at least one of the following: (i) symptoms of ischemia, or (ii) new or presumed new significant ST-segment–T wave (ST–T) changes or new left bundle branch block, or (iii) development of pathological Q waves in the electrocardiogram, or (iv) imaging evidence of new loss of viable myocardium or new regional wall motion abnormality, or (v) identification of an intracoronary thrombus by angiography or autopsy according

to the third universal definition of myocardial infarction. In our laboratory the cut-off value for troponin I was 0.04 µg/l.

2.4. DEFINITION OF DIABETES MELLITUS TYPE 2

Diabetes mellitus type 2 was defined according to current diagnostic criteria of the American Diabetes Association (ADA) (7) and the world health organization (WHO) (113) as the following:

Table 2.2: Major Diagnostic Criteria for Diabetes and Prediabetic or At-Risk States

Measure	American Diabetes Association		World Health Organization	
	Diabetes	Prediabetes	Diabetes	Impaired Glucose Regulation
Fasting plasma glucose	≥126 mg/dl	100–125 mg/dl (IFG)	≥126 mg/dl	110–125 mg/dl (IFG)
2h plasma glucose*	≥200 mg/dl	140–199 mg/dl (IGT)	≥200 mg/dl	140–199 mg/dl (IGT)
Casual (or random) plasma glucose**	≥200 mg/dl		≥200 mg/dl	
Glycated hemoglobin	≥6.5%	5.7–6.4%	≥6.5%	

* During an OGTT with a loading dose of 75 g

** In a patient with classic hyperglycemic symptoms

2.5. WESTERN BLOT

For immunodetection of MIF and GREM1 in platelet lysates were purified from platelets from peripheral blood sample of control subject with normal peripheral blood platelets. A standard immunodetection was performed on blotted proteins directly after electrotransfer. Protein concentration was determined using Biorad Protein Assay with protein standard BSA (Sigma) and measurement of absorption at 495 nm. The samples were diluted with Lämmli buffer (5x, +5% mercaptoethanol) and heated for 10 min up to 95°C. 30µg of total protein were separated on a 15% SDS-polyacrylamide gel electrophoresis (PAGE) (Invitrogen). Blotting of the protein onto a polyvinylidenedifluoride membrane (PVDF, Immibilon, Millipore) was performed using Semi Dry Transfer Cell System (PeqLab). As primary antibody Recombinant Human MIF polyclonal antibody from RD Systems was used in 1:7500 dilution in 5% milk/ Phosphate buffered saline (PBS) was used for detection of MIF and purified rabbit polyclonal GREMLIN (C-Term) antibody from Abgent for detection of GREMLIN1. β -actin antibody (Sigma-Aldrich, Steinheim, Germany) and α -actin antibody (polyclonal) (Abcam, Cambridge, UK) were used as internal loading control. For detection of antibody binding, corresponding secondary fluorescence labeled antibodies and the Odyssey infrared imaging system (LI-COR, Bad Homburg, Germany) were used. Bands were quantified using ImageJ software (National Institutes of Health, USA).

2.6. FLUORESCENCE-ACTIVATED CELL SORTING (FACS)

Fluorescence-activated cell sorting was used to quantify the expression of MIF and GREM1 from platelets of the subjects. We aimed to quantify the expression of the proteins in both stimulated (with 20 µmol/l ADP) and naïve platelets

collected from full blood in sodium citrate tubes. 20µL blood were diluted in 980 µL PBS and 40 µL were aliquoted in every tube.

Activation

The activation of the platelets was performed with 20 µmol/l ADP in a 1:5 ADP: blood volume concentration. After pipetting ADP, the dilute was gently swirled to mix and was incubated in a dark room at room temperature. After 30 minutes 2.5 µL 10% paraformaldehyde (PFA) solution was used to fixate the cells.

Multicolour Direct Immunofluorescence Staining

This protocol followed the same steps for unstimulated and activated fixed whole blood suspension. After the 2.5 µL 10% PFA solution was added, 5 µL of CD42a platelet-specific antibody conjugate were used to threshold data acquisition to analyze only platelets. 5µL 1% Triton X-100 ($C_{14}H_{22}O(C_2H_4O)_n$) was used to permeabilize the platelet cell membranes for the tubes, where MIF and GREM1 expression was investigated, as preliminary tests had shown better results with permeabilized cells in flow cytometry. Another antibody conjugated to a different fluorochrome, fluorescein isothiocyanate (FITC), was used to simultaneously assess the binding of platelet-associated antibodies. For the scope of this study following antibodies were used:

1. Activation-dependent antibodies alpha2b-beta3 (PAC-1) (BD Biosciences), P-selectin (CD62P) (R&D Systems) and Stromal Cell-Derived Factor 1 (SDF-1) (Abcam)
2. MIF (Abcam)
3. GREM1 (Abcam)

After an incubation period of 30 minutes in a dark room at room temperature the conjugated platelets were fixated with 300 µL PFA 0.5% and the tubes were stored at 4° C, protected from light for at least 30 minutes, but not more than 48

hours. Right before flow cytometry, samples were vortexed for at least 10 seconds to gain a proper suspension.

2.7. IMPEDANCE PLATELET AGGREGOMETRY

The Multiplate® analyzer, a whole blood platelet function assay, was used to study the platelet aggregation level. 900µL blood acquired in hirudinized tubes (Sarstedt) was needed to perform ADPtest, ASPItest and TRAPtest in each patient. The Multiplate® test principle is based on an advancement of Cardinal and Flower's 1979 impedance aggregometry method, the Multiple Electrode Aggregometry (MEA)(86). We used the area under the aggregation curve (AUC) to express the overall platelet aggregation. U was used as unit for AUC (1 Unit * 10 AUC). Tests were performed at least 30 minutes after blood acquisition, but not longer than 3 hours later.

Table 2.3: Reagents used in impedance platelet aggregometry.

Reagent	Description
ADPtest	ADP induced platelet activation sensitive to clopidogrel, prasugrel and other ADP receptor antagonists
ASPItest	Cyclooxygenase dependent aggregation (using arachidonic acid) sensitive to Aspirin®, NSAIDs and other inhibitors of platelet cyclooxygenase
TRAPtest	Platelet stimulation via the thrombin receptor (using TRAP-6), sensitive to IIb/IIIa receptor antagonists (95)

3. RESULTS

3.1. MIF IS EXPRESSED IN HUMAN PLATELETS

3.1.1. DETECTION OF MIF BY WESTERN BLOT

To determine whether MIF is expressed in normal platelets protein was harvested from cell lysates and western blot was performed (Fig. 3.1). Blots were probed with an anti-MIF rabbit polyclonal antibody and an anti- β actin antibody. A specific anti-MIF antibody recognized a single band of approximately 12.5 kDa in all specimens tested in resting and activated platelets. Peripheral-blood platelets from healthy blood donors were used as controls.





Figure 3.1: Qualitative study of MIF expression in platelets

Western blot analysis of lysates derived from purified platelets from a peripheral blood sample from a control subject with normal peripheral blood platelets for the expression of MIF. Reducing conditions, 15% SDS-Page, blocking in 5 % milk/PBS, (A) 1st Ab Anti-MIF (RD Systems) 1:100 in 5% milk/PBS, (B) 2nd Ab 1:7500 in 5% milk/PBS.

3.1.2. IMMUNOFLUORESCENCE MEASUREMENTS OF MIF BY FACS

Quantitative platelet MIF expression was analyzed by flow cytometry. Flow cytometry analysis confirmed the expression of MIF in the three main blood cell lineages and a two-color analysis revealed that MIF was highly expressed on platelets that were stained with CD42b. CD42b positive cells demonstrated prominent surface staining (Figure 3.2.). Before the double staining procedure one sample was activated with ADP and one was left in the resting state. The total level of fluorescence on a per cell basis was not significantly altered.

A



B




Figure 3.2: Flow cytometric analysis of the expression of MIF

Panel A shows flow cytometric plots of whole blood. In the left-hand plot, forward and side scatter is demonstrated. The histogram on the right represents the expression of CD42b by the three main blood cell lineages.

Panel B The left-hand plot shows the expression of CD42b on gated MIF cells, with two regions showing the CD42+ and CD42b- cell subpopulations. The

histogram on the right represents the expression of MIF by the CD42b+ subpopulation.

3.2. GREM1 IS EXPRESSED IN HUMAN PLATELETS

3.2.1. DETECTION OF GREM1 BY WESTERN BLOT

To determine qualitative expression of GREM1 in platelets, protein was harvested from cell lysates and western blot was performed (Fig. 3.3.). Blots were probed with an anti-GREM1 rabbit polyclonal antibody and an anti- β actin antibody. A specific anti-GREM1 antibody recognized a single band of approximately 20.7 kDa followed with a double band of approximately 25 kDa in all specimens tested in resting and activated platelets.





Figure 3.3: Qualitative expression of GREM1 in platelets

Western blot analysis of lysates derived from purified platelets from a peripheral blood sample from a control subject showing expression of GREM1 in platelets. Reducing conditions, 15% SDS-Page, blocking in 5 % milk/PBS, (A) Ab Anti-Gremlin (Abgent) 1:100 in 5% milk/PBS, (B) Ab 1:7500 in 5% milk/PBS.

3.2.2. IMMUNOFLUORESCENCE MEASUREMENTS OF GREM1 BY FACS

Platelet GREM1 expression was analyzed by two-colour flow cytometry with simultaneous staining with CD42b. Platelets were studied in both resting and activated state without an alteration of total level fluorescence on a per cell basis.

A



B




Figure 3.4: Flow cytometric Analysis of the Expression of GREM1

Panel A shows flow cytometric plots of whole blood. In the left-hand plot, forward and side scatter of blood is demonstrated. The histogram on the right represents the expression of CD42b by all cell subpopulations.

Panel B The left-hand plot shows the expression of CD42b on gated GREM1 cells, with two regions showing the CD42+ and CD42b- cell subpopulations. The histogram on the right represents the expression of GREM1 by the CD42b+ subpopulation.

3.3. STUDY SUBJECTS' CHARACTERISTICS

The study included 300 CAD patients. Mean study participant age was 67.7 years and more than fifty per cent were of age older than 70 years. More than three quarters were men, with women on average being older than men with a mean age of 71.8 (\pm 10.4) years versus 66.4 (\pm 11.6) years. Mean body-mass index was 29.2 (\pm 18.9). One quarter of the subjects were active smokers when enrolled in the study, while 54.3% of them had never been smokers. Diabetes mellitus was common between subjects, with 31.7% having some form of insulin resistance. Amongst the diabetics those under therapy with oral anti-diabetic agents had the poorest control of blood glucose levels and those under insulin the best one (HbA1c: 8.63 (\pm 2.3) g/dL versus 8.09 (\pm 0.96) g/dL). From the 95 diabetics 51 (54%) had a HbA1c over 7 g/dL. The mean total cholesterol levels were 176.4 (\pm 41.8) mmol/L with LDL 129.5 (\pm 39.2) mmol/L. Fifty five subjects suffered from chronic kidney disease with a mean serum creatinine value of 1.54 (\pm 1.5) mg/dL and mean serum Urea value of 55.69 (\pm 25.4) mg/dL. Patients without known chronic kidney disease had a mean serum creatinine value of 0.93 (\pm 0.2) mg/dL. More than 25% of the subjects had some family history of coronary artery disease and 78.7% had hypertension requiring medication. Table 3.1. shows the patients' characteristics.

Table 3.1. Baseline characteristics of the patient cohort

Characteristic	Total (300)
<i>Age</i>	
30–59 years	72
60–69 years	71
\geq 70 years	155

Mean age — yr.	67.7 (\pm 11.6)
<i>Sex</i>	
Male sex — no. (%)	228 (76)
Female sex — no. (%)	72 (24)
BMI † — mean kg/m ²	29.2 (\pm 18.9)
<i>Smoking status</i>	
Current smoker — no. (%)	75 (25)
Former smoker — no. (%)	62 (20.7)
Never smoker — no. (%)	163 (54.3)
<i>History of diabetes — no. (%)</i>	
No known diabetes — no. (%)	205 (68.3)
Type 1 diabetes — no. (%)	0
Type 2 diabetes — no. (%)	95 (31.7)
Low glycemic index diet — no. (%)	20 (6.7)
Oral anti-diabetic medication — no. (%)	38 (12.7)
Insulin — no. (%)	37 (12.3)
HbA1c (g/dL), median (IQR‡)	7.2 (\pm 4.2)
HbA1c > 7 g/dL	51
Total cholesterol — mg/dL	176.4 (\pm 41.8)
LDL cholesterol	129.5 (\pm 39.2)
Chronic kidney disease — no. (%)	55 (18.3)
Serum creatinine value (mg/dL), median (IQR‡)	1.05 (\pm 0.7)
Family history of coronary artery disease — no. (%)	79 (26.3)

Hypertension requiring medication — no. (%)	236 (78.7)
<i>Clinical presentation</i>	
Stable angina pectoris — no. (%)	131 (43.6)
Unstable angina pectoris — no. (%)	67 (22.3)
NSTEMI — no. (%)	69 (23)
STEMI — no. (%)	33 (11)
History of known coronary artery disease — no. (%)	248 (82.7)
NYHA I	140 (46.7)
NYHA II	101 (33.7)
NYHA III	41 (13.7)
NYHA IV	18 (6)
Ejection fraction	47.14 (\pm 10.6)
Atrial fibrillation	58 (19.3)
Log _e CRP† — mg/liter	
CRP Day 0 (mg/dl), median (IQR‡)	1.62 (\pm 3.9)
<i>Biomarkers of cardiac injury</i>	
Troponin I _{max} (μ g/dL)	5 (\pm 28.4)
Creatinine kinase (mg/dL)	276.9 (\pm 668.2)
<i>Medication on presentation</i>	
Aspirin	179 (59.7)
Anticoagulants	27 (9)
Clopidogrel	37 (12.3)
Prasugrel	7 (2.3)

* Values represent means \pm SD.

† BMI=body-mass index

‡IQR, Interquartile range

‡CRP, C-reactive protein

131 elective patients with stable CAD were included in this cohort. 40 of them had a myocardial infarction in their medical history at a mean of 5.5 years before their current presentation. The mean left ventricular ejection fraction in this group was 45.9 (\pm 10.6) % and the mean age was 68.23 (\pm 10.6) years. The distribution of weight was normal with a mean weight of 83.3 kg and standard deviation of 13.6 kg. Their mean BMI was 28.7 (\pm 4.37) kg/m², their mean LDL 127.56 (\pm 44.7) mmol/L, their Creatinine 0.97 (\pm 0.26) mg/dL and 43 of them were diabetics. Furthermore they had a Creatinine kinase within the normal with 107.23 (\pm 62.7) U/L and a CRP of 0.6 (\pm 0.88) mg/dL.

The remaining 169 patients presented with an acute coronary syndrome. 67 patients or 22.3% were diagnosed with an unstable angina pectoris, 69 or 23% with a non ST-Segment Elevation Acute Coronary Syndrome and 33 patients or 11% presented with ST-segment elevation acute myocardial infarction. Patients with unstable angina pectoris were the oldest group with a mean age of 70.78 (\pm 10.49) years and patients with STEMI were the youngest group with a mean age of 61.29 (\pm 12.27) years. Furthermore, left ventricular ejection fraction was most impaired in the STEMI group with a mean EF of 47.85 (\pm 6.53) % and less impaired in the unstable angina group, where the patients had a mean EF of 49.48 (\pm 11.33) %. Overall the STEMI group included the least multimorbid patients in the ACS-group, including better renal function (mean Creatinine of 1 (\pm 0.64) mg/dL versus 1.2 (\pm 1.3) mg/dL in the unstable angina pectoris group

and 1.04 (\pm 0.35) mg/dL in the NSTEMI-group), better glucose control (with mean glyated hemoglobin of 5.19 (\pm 1.6) % versus 6.46 (\pm 1.01)% in the unstable angina group and 7.44 (\pm 1.74)% in the NSTEMI group) and less obese patients (with mean BMI of 25.55 (\pm 1.84) kg/m² versus 27.18 (\pm 3.64) kg/m² in the unstable angina group and 28.06 (\pm 5.28) kg/m²).

Depending on their diabetes status patients were classified in non-diabetics, patients with diabetes that requires lifestyle changes to control, diabetics who need oral agents to control their glucose levels and patients who require treatment with insulin. There were 95 diabetics included in this study. Diabetics were in general older with a mean age of 70.8 (\pm 10.2) years versus 66.3 (\pm 11.9) years for the non-diabetics, without any statistical significance (p= 0.54). They had a slightly worse ejection fraction with 49.25 (\pm 11.2)% versus 51.25 (\pm 11.5)%, also with no statistical significance (p= 0.585). Furthermore diabetics had a slightly higher BMI with a mean of 28.95 (\pm 5.26) kg/m² versus 27.57 (\pm 3.8) kg/m² (p= 0.009). Their LDL-Cholesterol levels were better controlled, since more of them were under therapy with statins (124.34 (\pm 32.4) mg/dL in diabetics versus 131.99 (\pm 42.1) mg/dL in non-diabetics, p= 0.143). The levels of C-reactive protein in diabetics were slightly higher in comparison with non-diabetics (2.04 (\pm 4.7) mg/dL in diabetics versus 1.42 (\pm 3.4) mg/dL in non-diabetics, p= 0.44). Mean serum creatinine levels did not differ significantly with diabetics having a mean creatinine of 1.09 (\pm 0.42) mg/dL and non-diabetics 1.03 (\pm 0.8) mg/dL (p= 0.381). The following table sums up the characteristics of the cohort according to their diabetes status.

Table 3.2. Baseline Characteristics according to diabetes status

Characteristic	Diabetics (95)	Nondiabetics (205)
Mean age — yr.	70.82 (\pm 10.2)	66.3 (\pm 11.9)
Male sex — no. (%)	66 (69.5)	162 (79)

BMI † — mean kg/m ²	28.9 (± 5.3)	27.6 (± 3.8)
<i>Smoking status</i>		
Current smoker — no. (%)	14 (14.7)	61 (29.8)
Former smoker — no. (%)	21 (22.1)	41 (20)
Never smoker — no. (%)	60 (63.2)	103 (50.2)
HbA1c (g/dL), median (IQR‡)	8.3 (± 5.4)	5.8 (± 0.5)
Total cholesterol — mg/dL	169 (±34)	179.9 (44.7)
LDL cholesterol — mg/dL	124.34 (±32.4)	132 (±42.1)
Chronic kidney disease — no. (%)	30 (31.6)	25 (12.2)
Serum creatinine value (mg/dL), median (IQR‡)	1.09 (±0.4)	1.03 (± 0.8)
Family history of coronary artery disease — no. (%)	20 (21.1)	59 (28.8)
Hypertension requiring medication — no. (%)	82 (86.3)	154 (75.1)
<i>Clinical presentation</i>		
Stable angina pectoris — no. (%)	13 (45.3)	88 (42.9)
Unstable angina pectoris — no. (%)	20 (21.1)	47 (22.9)
NSTEMI — no. (%)	25 (26.3)	44 (21.5)
STEMI — no. (%)	7 (7.4)	26 (12.7)
History of known coronary artery disease — no. (%)	86 (90.5)	162 (79)
NYHA I	40 (42.1)	100 (48.8)
NYHA II	34 (35.8)	67 (32.7)

NYHA III	12 (12.6)	29 (14.1)
NYHA IV	9 (9.5)	9 (4.4)
Ejection fraction	49.25 (\pm 11.2)	51.21(\pm 11.5)
Atrial fibrillation	32 (33.7)	26 (12.7)
Baseline CRP (mg/dl), median (IQR \ddagger)	2.04 (\pm 4.7)	1.42 (\pm 3.36)
<i>Biomarkers of cardiac injury</i>		
Troponin I _{max} (μ g/dL)	11.26 (\pm 21.73)	24.49 (\pm 51.05)
Creatinine kinase _{max} (mg/dL)	526.8 (\pm 1177)	712.6(\pm 1009)
<i>Medication on presentation</i>		
Aspirin	68 (71.6)	111 (54.1)
Anticoagulants	13 (13.7)	14 (6.8)
Clopidogrel	12 (12.6)	4 (2)
Prasugrel	3 (3.2)	4 (2)
Ticagrelor	7 (7.4)	5 (2.4)

* Plus-minus values are means \pm SD.

† BMI=body-mass index

\ddagger IQR, Interquartile range

‡CRP, C-reactive protein

3.4. PLATELET MIF AND GREM1 EXPRESSION ARE INDEPENDENT OF PLATELET COUNT

In our cohort the mean platelet count was 250 (\pm 74) thousands/ μ L. We found that expression of MIF in platelets was independent from platelet count with a mean MFI value of 17.76 (\pm 9.7) and a p value of 0.222. In activated state the mean MFI value for the expression of MIF was 16.63 (\pm 11.38) ($p=$ 0.419). For GREM1 from resting platelets a mean MFI of 15.38 (\pm 7.49) was found ($p=$ 0.530), whereas for GREM1 from platelets activated with ADP the mean MFI value was 16.14 (\pm 9.48) ($p=$ 0.338).




Figure 3.5: Scatterplot presenting the correlation of the mean values of MFI of MIF (above) and GREM1 (below) with the platelet count in our cohort.

3.5. PLATELETS STIMULATED WITH ADP PRODUCE DIFFERENT AMOUNTS OF MIF AND GREM1

We compared the expression of MIF and GREM1 in resting and activated platelets. The platelets were activated with ADP before staining as described above. MIF levels in resting platelets were 17.98 (\pm 9.8), while in activated ones

16.9 (\pm 11.7). GREM1 levels in resting platelets were at mean 15.58 (\pm 7.7) and in activated ones 16.53 (\pm 10.6) MFI. The levels of MIF and MIF + ADP correlated significantly with a p value of 0.006 and a correlation coefficient of 0.706. The levels of GREM1 and GREM1 + ADP also correlated significantly with a p value of 0.004 and a correlation coefficient of 0.743.




Figure 3.6: Scatterplots presenting the correlation of the mean values of MFI of MIF with MIF in platelets stimulated with ADP (above) and GREM1 in resting platelets and GREM1 in platelets stimulated with ADP (below) in our cohort. R^2 coefficient of determination was 0.706 for MIF and 0.743 for GREM1.

3.6. THE LEVELS OF MIF EXPRESSED BY PLATELETS CORRELATES WITH THE EXPRESSION OF GREM1 IN THE SAME PATIENT

Our cohort expressed MIF from platelets with a mean MFI value of 17.98 (± 9.77) and GREM1 with a mean MFI value of 15.65 (± 8.08). These mean values correlated significantly in our patients with a p value <0.001 .




Figure 3.7: Scatterplot presenting the correlation of the mean values of MFI of MIF and GREM1 in our cohort. R^2 coefficient of determination was 0.48.

3.7. P-SELECTIN PLATELET EXPRESSION CORRELATES WITH MIF AND GREM1 EXPRESSION

We compared the expression of P-selectin with the expression of MIF. MIF levels were found higher in patients with high CD62P-expression (18.55 ± 9.9 versus 13.28 ± 6.42 , $p= 0.044$). Platelets that showed a high expression of P-selectin appeared to also express higher amounts of Gremlin-1 (14.9 ± 6.2 versus 10.4 ± 2.6 , $p=0.03$).




Figure 3.8: Scatterplots presenting the correlation of the mean fluorescence intensity of MIF (left) and GREM1 (84) with values for P-selectin in our cohort. R2 coefficient of determination was 0.223 for MIF ($p=0.044$) and 0.264 for GREM1 ($p=0.03$).

3.8. PLATELET REACTIVITY AS MEASURED WITH MULTIPLATE® ANALYSER WAS INDEPENDENT FROM MIF AND GREM1 EXPRESSION

MIF and GREM1 expression in resting and activated platelets did not correlate with platelet aggregation induced with ADP, ASPI or TRAP-6 as measured with the Multiplate® analyzer. For MIF and ADP-test the Pearson correlation was 0.021 ($p= 0.747$) for resting and 0.049 ($p= 0.447$) for stimulated platelets. For GREM1 and ADP-test the Pearson correlation coefficient was 0.051 ($p= 0.383$) for resting and 0.067 ($p= 0.256$) for stimulated platelets. The ASPI and TRAP-6 tests yielded comparable results with ASPI-test units showing no correlation neither with MIF or GREM1 levels ($p= 0.933$ and 0.675 in resting platelets and $p= 0.606$ and 0.870 in stimulated platelets, respectively). P values for correlation with TRAP-induced aggregation were 0.89 for MIF in resting platelets and 0.931 in stimulated ones and for GREM1 0.491 and 0.672, respectively.

When 40 AUC (Area Under the Curve) was used as cut-off value for high platelet reactivity (HPR) in patients on both aspirin and an ADP-receptor inhibitor, no correlation of HPR with GREM1 and MIF levels was found. This cut-off value was selected according to the consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate state of art paper and the experience of our institution (86, 137, 138, 141)

Patients with HPR had a mean MIF value of 16.66 (\pm 10.6) versus 16.59 (\pm 6.98), $p= 0.038$. GREM1 levels were found with a mean value of 17.91 (\pm 9.67) in patients with HPR and 14.58 (\pm 7.19) in patients with and less than 40 AUC at ADP-test ($p= 0.077$).




Figure 3.9: Scatterplots presenting the correlation of the mean fluorescence intensity of MIF and GREM1 with values of platelet aggregation as measured after stimulation with ADP (AUC) in our cohort.

3.9. LEVELS OF MIF AND GREM1 EXPRESSION FROM PLATELETS CORRELATE WITH THE LEVELS OF GLYCOPROTEIN VI EXPRESSION FROM PLATELETS

There was a weak correlation between platelet MIF and Glycoprotein VI expression as shown with a Pearson-test value of 0.249 or $p<0.001$ in resting

platelets and 0.148 or $p=0.023$ in stimulated platelets. Correlation between GREM1 and Glycoprotein VI was also found to be statistically significant with p values of <0.001 for resting and 0.003 for activated platelets.




Figure 3.10: Scatterplots presenting the correlation of the mean values of MFI of MIF (above) and GREM1 (below) with a mean fluorescence intensity of SDF-1 in our cohort.


3.10. LEVELS OF MIF AND GREM1 EXPRESSION FROM PLATELETS CORRELATE WITH THE LEVELS OF PAC-1 EXPRESSION FROM PLATELETS

There was a correlation between platelet MIF and PAC-1 expression as shown with a Pearson-test value of 0.498 or $p < 0.001$ in resting platelets and 0.517 or $p < 0.001$ in stimulated platelets. Correlation between GREM1 and PAC-1 was also found to be statistically significant with p values of < 0.001 for resting ($r_s = 0.364$) and activated ($r_s = 0.417$) platelets. Platelets with high amount of PAC-1 had a high amount of MIF and GREM1 (MIF: 24.6 (± 11.4) MFI versus 15.8 (± 8) MFI, GREM1: 19.7 (± 11.4) MFI versus 14.1 (± 5.4) MFI).

3.11. LEVELS OF GREM1 EXPRESSION FROM PLATELETS AND PLASMA LEVELS CORRELATE WITH CARDIAC NECROSIS MARKER CREATININE KINASE

Levels of platelet bound GREM1 showed a weak correlation with the maximum creatinine kinase values with a correlation coefficient of 0.174 and a p value of 0.047. Levels of plasma GREM1 showed a correlation with the creatinine kinase levels with a correlation coefficient of 0.158 and a p value of 0.038.

A



B




Figure 3.11: Scatterplot presenting the correlation of the values of plasma levels of GREM1 (A) and mean MFI values of platelet GREM1 (B) with creatinine kinase in our cohort.

3.12. LEVELS OF GREM1 AND MIF EXPRESSION FROM PLATELETS CORRELATE WITH TROPONIN I

Levels of GREM1 showed a statistical correlation with the maximum values of Troponin I with a correlation coefficient of 0.243 ($p= 0.006$), while MIF and Troponin levels had a correlation coefficient of 0.233 ($p= 0.014$). Patients with positive troponin tests (cut-off $0.004 \mu\text{g/dL}$) showed lower expression of MIF and GREM1 in their platelets with mean MFI values of $16.59 (\pm 9.8)$ versus $18.96 (\pm 9.8)$ for MIF and $14.42(\pm 7)$ versus $16.21 (\pm 7.9)$ for GREM1.




Figure 3.12: Scatterplots presenting the correlation of the mean MFI values of MIF (left) and GREM1 (84) to Troponin values in patients with positive Troponin-test in our cohort.

3.13. LEVELS OF SERUM CRP, MIF AND GREM1 EXPRESSION FROM PLATELETS ARE INCREASED IN DIABETICS

We observed that C-reactive protein levels are increased in diabetics in comparison to non-diabetics. Diabetics had a mean CRP in serum of $2.04 (\pm 4.715)$ mg/dL in comparison to non-diabetics that had a mean serum CRP of $1.42 (\pm 3.356)$ mg/dL. This difference was found statistically significant with a p value of 0.044. Platelets of diabetics expressed MIF significantly more with a

mean MFI value of 18.67 (\pm 11.257) in comparison to non-diabetics, whose platelets expressed MIF with a mean MFI value of 17.66 (\pm 9.03) ($p= 0.004$). GREM1 was also expressed stronger in platelets of diabetics with a mean MFI value of 15.78 (\pm 8.399) versus 15.49 (\pm 7.428) in those of non-diabetic patients. ($p=0.022$).




Figure 3.13: Clustered bar presenting the mean values of CRP, MIF and GREM1 and the standard error of the mean in correlation with diabetic status of the subjects.

3.14. ONGOING THERAPY REGIMENT FOR DIABETES DID NOT CORRELATE WITH THE EXPRESSION OF MIF FROM PLATELETS

The expression of MIF showed no significant intergroup differences in platelets of diabetics undergoing lifestyle changes to control their glucose levels and platelets of diabetics requiring oral antidiabetic drugs (mean MFI 16,65 (\pm 11,2) versus 18.6 (\pm 9.7), $p=$ 0.366). MIF expression levels of diabetics requiring therapy with insulin were as high as 19.8 (\pm 12.7), but the difference showed no statistical significance with a p value of 0.201 when compared to diabetics using oral antidiabetic drugs and a p value of 0.773 when compared with those undergoing lifestyle changes. A trend of increased MIF expression from platelets depending to the therapeutic regiment required was just arithmetically apparent.

3.15. MIF EXPRESSION FROM PLATELETS CORRELATES WITH THE SUCCESS IN CONTROLLING GLUCOSE LEVELS IN CAD PATIENTS

A comparison of MIF levels with the quality of glucose level controls, using HbA1c, showed a statistical correlation. MIF was expressed stronger in platelets of patients with a poor control of their diabetes with a mean MFI value of 20.94 (\pm 12.32) versus 13.65 (\pm 4.1) in those with an HbA1c lower than 7% ($p=$ 0.003).




Figure 3.14: Bar chart representing MFI of MIF from resting and MIF from activated platelets with HbA1c as the discrete data set, stratifying patients to those with well controlled diabetes (HbA1c <7%) and those with poor control over their average plasma glucose concentration (HbA1c ≥7%).

3.16. GREM1 EXPRESSION IN PLATELETS CORRELATES WITH THE SUCCESS IN CONTROLLING GLUCOSE LEVELS IN CAD PATIENTS

The expression of GREM1 in platelets showed a statistical increase in patients with poorly controlled diabetes mellitus independent of the therapy. This increase was present in both resting and activated platelets. For patients with an HbA1c ≥7% GREM1 expression in resting platelets had a mean MFI value of 17.98 (± 10.82) versus 13.65 (±4.1) in those with control over their average plasma glucose concentration (p= 0.005). In activated platelets of patients with poorly controlled diabetes GREM1 was expressed with a mean MFI value of

19.82 (\pm 13.56) versus 13.23 (\pm 5.4) in those with an HbA1c under 7% ($p=$ 0.001).




Figure 3.15: Bar chart representing MFI of GREM1 from resting and GREM1 from activated platelets with HbA1c as the discrete data set, stratifying patients to those with well controlled diabetes (HbA1c <7%) and those with poor control over their average plasma glucose concentration (HbA1c \geq 7%).

3.17. MIF AND GREM1 PLATELET LEVELS ARE LOWER IN PATIENTS WITH IMPAIRED EJECTION FRACTION

The ejection fraction as assessed by contrast ventriculography correlated with the mean MIF levels in resting platelets and activated ones. Quiescent platelet from patients with left ventricular dysfunction (ejection fraction (<45%) express less MIF with a mean MFI of 3.4 (\pm 0.7) versus 4.1 (\pm 1) MFI in those without a relevant impairment ($p < 0.001$). Activated platelets also expressed less MIF in

patients with left ventricular dysfunction with a mean MFI of 3.2 (\pm 0.8) versus 3.9 (\pm 1) mean MFI in those without a relevant impairment ($p < 0.001$).

GREM1 expression in platelets of patients with left ventricular dysfunction was decreased in comparison with patients with no relevant left heart failure, with mean MFI 3.5 (\pm 0.4) versus 3.9 (\pm 0.8) ($p = 0.005$) for resting platelets and mean MFI 3.6 (\pm 0.6) versus 3.9 (\pm 1) for activated platelets ($p = 0.046$).

3.18. MIF AND GREM1 PLATELET LEVELS ARE SIGNIFICANTLY LOWER IN ACS PATIENTS WITH IMPAIRED EJECTION FRACTION

Patients suffering from systolic heart failure during an ACS have significantly lower levels of platelet MIF and GREM1. Patients in heart failure were considered patients with an ejection fraction under 45% as assessed by cardiac ventriculography.

Platelet MIF expression in patients with left ventricular dysfunction during an ACS was decreased in comparison with patients with no relevant left heart failure, with a mean MFI 3.35 (\pm 0.8) versus 4 (\pm 1) ($p = 0.004$) for resting platelets and mean MFI 3.1 (\pm 0.8) versus 3.9 (\pm 1) for activated platelets respectively ($p = 0.001$). Platelet GREM1 expression in patients with left ventricular dysfunction during an ACS was decreased in comparison with patients with no relevant left heart failure, with a mean MFI 3.4 (\pm 0.4) versus 3.9 (\pm 0.9) respectively ($p = 0.008$).




Figure 3.16: Bar chart presenting the correlation of MIF and GREM1 in platelets with the ejection fraction assessed by ventriculography. We classified impaired left ventricular function as left ventricular ejection fraction <45 percent and as non-impaired EF ≥45%.

3.19. THE CLINICAL PRESENTATION OF IHD CORRELATES WITH THE LEVELS OF MIF AND GREM1 EXPRESSED BY PLATELETS

The different clinical presentations of ischemic heart disease were found to correlate highly with MIF and GREM1 levels in resting and activated platelets. Platelet levels of MIF decrease as the acuteness of the ischemic disease increases. Mean MFI value of MIF in patients with stable angina was 4.3 (\pm 1), in patients with unstable angina 4.1 (\pm 1.2), in patients with non-STEMI infarction was 3.8 (\pm 1.1) and in patients presenting with an ST-elevation ACS was found the lowest with a mean value of 3.8 (\pm 0.9). The difference between

expression of MIF in stable CAD and heart attacks was statistically significant with a p value of 0.006 for stable CAD and NSTEMI and 0.034 for stable CAD and STEMI.

GREM1 levels in stable ischemic heart disease were found at a mean value of 3.9 (\pm 0.8) MFI when in STEMI patients 3.6 (\pm 0.7) MFI ($p=0.028$).

MIF levels in platelets of patients with ACS were 3.9 (\pm 1.1) MFI versus 4.3 (\pm 1) MFI in patients with a stable angina ($p= 0.008$). GREM1 platelet expression in patients with ACS was found lower with a mean MFI of 15.3 (\pm 8.4) versus 16 (\pm 6.8) in patients with a stable CAD ($p=0.029$).




Figure 3.17: Bar chart representing the mean MFI for MIF (white) and GREM1 (black) depending on the presence of ACS.

3.20. PLASMA LEVELS OF GREM1 CORRELATE WITH PLASMA CRP LEVELS

GREM1 levels in serum as evaluated with ELISA showed a correlation with C-reactive protein levels with a Spearman's rho of 0.179 and a p value of 0.014. A non-parametric test was used because CRP values had a skewed distribution and also allows for inclusion of outliers. The cut-off value used for CRP was 0.5 mg/dL. Patients with positive CRP had a mean GREM1 of 288 (\pm 137) pg/mL and patients with CRP values under 0.5 mg/dL had a mean GREM1 value of 249 (\pm 132) pg/mL.

3.21. PLASMA LEVELS OF GREM1 AND MIF WERE INDEPENDENT OF WHITE BLOOD CELL COUNT

Total white blood cell count did not affect plasma levels of both GREM1 and MIF with a correlation coefficient for MIF of 0.47 ($p= 0.532$) and for GREM1 of 0.85 ($p= 0.250$).

3.22. PLASMA LEVELS OF GREM1 CORRELATED WITH RENAL FUNCTION MARKER

Plasma levels of GREM1 showed a weak correlation with the values for serum creatinine with a correlation coefficient of 0.178 and p-value of 0.015 and with the serum urea levels with a correlation coefficient of 0.216 with a p-value of 0.006.

3.23. PLATELET BOUND GREM1 AND MIF EXPRESSION IS INDEPENDENT OF CONCOMITANT MEDICATION

The platelet expression of MIF in patients under aspirin-therapy was compared to the MIF expression of aspirin-naïve patients and no significant difference was found ($p= 0.105$). The platelet expression of MIF in patients under dual antiplatelet regiment with aspirin and a P2Y₁₂-inhibitor was compared to patients' naïve to both medications and no significant difference was found ($p= 0.154$ for clopidogrel, $p= 0.790$ for prasugrel and $p= 0.618$ for ticagrelor). The platelet expression of GREM1 in patients under aspirin-therapy was compared to the GREM1 expression of aspirin-naïve patients and no significant difference was found ($p= 0.203$). The platelet expression of GREM1 in patients under dual antiplatelet regiment with aspirin and a P2Y₁₂-inhibitor was compared to patients' naïve to both medications and no significant difference was found ($p= 0.998$ for clopidogrel, $p= 0.859$ for prasugrel and $p= 0.405$ for ticagrelor).

4. DISCUSSION

4.1. MIF IN CORONARY ARTERY DISEASE AND TYPE 2 DIABETES MELLITUS

In this study we concentrated on the atherogenic function of MIF. The role of monocytes, T-cells and activated endothelium in the circle of MIF-expression has already been broadly implicated in atherosclerosis. Our group has managed to show that plasma MIF expression is enhanced in ACS, is associated with various markers of inflammation and that it correlated with cardiac necrosis markers after PCI (110). In other studies it has been shown that genetic manipulation and deletion of MIF in atherosclerosis susceptible mice protected the heart from severe ischemia-reperfusion injury through suppression of inflammatory responses (63).

This study provides new knowledge concerning the clinical role of platelet bound MIF in cardiovascular disease. Many mechanisms of MIF in atherosclerosis have been proposed; promotion of atherogenic leukocyte recruitment processes has been recognized as a major underlying mechanism of the role of MIF in plaque instability (23, 136).

Vascular injury might precede atherothrombosis and MIF has been proved to regulate the biological response to injured tissue. In a study model of carotid artery injury in atherosclerosis-susceptible mice MIF was shown to promote thickening of the neointima through accumulation of inflammatory cells and proliferation of the media and intima layer (34). A study about the interaction of MIF with AMP-activated protein kinase (AMPK) suggested a critical role for MIF in the cardiomyocyte response to ischemia, implicating MIF-release genes in ATP-regulation in cardiomyocytes and suggesting MIF genes as a diagnostic target in risk stratification for CAD (105).

Platelets are recruited to the site of vascular injury to fulfill their hemostatic role, but also at sites of activated, inflamed but still intact endothelium and promote atherosclerosis (21). Platelets are a major part of thrombi in acute myocardial infarctions and their proinflammatory mediators might contribute to fibrosis and systolic dysfunction following myocardial infarctions (101). Thus, the expression and regulation of the expression of MIF from platelets poses an interesting investigational target.

In several clinical studies serum MIF levels correlated with insulin resistance and metabolic syndrome, providing support for a role of MIF in the development of insulin resistance and T2DM (76, 158). However, in the large Finnish Diabetes Prevention Study which tested lifestyle intervention in patients with BMI > 25 kg/m² with impaired glucose tolerance, MIF was not associated with the risk of T2DM in the control group and subjects with high MIF had lower risk for T2DM (77). Clinical studies so far have suggested an important link between MIF, obesity, insulin resistance and T2DM, but it is not clear if the MIF expression irregularities are epiphenomena or casual factors. Animal studies showed that MIF-Knockout mice had increased glucose uptake into white adipose tissue, with MIF inhibiting insulin signal transduction, overall suggesting an important role for MIF in the regulation of systemic glucose metabolism during infection and tissue invasion (10).

There is a growing body of evidence on platelets and their role in the progression of the atherosclerotic procedure through modulation of immune responses. Many pathways for that interaction have been suggested such as the OxLDL-mediated platelet-monocyte aggregate formation theory highlighting the role of platelets in atherosclerotic plaque development and plaque destabilization (11, 14). This project is based on an observation that platelets contain significant amounts of MIF and GREM1.

Chronic low-grade inflammation is a hallmark of T2DM, a process guided from cytokines, including the macrophage migration inhibitory factor. The role of MIF

in T2DM has been extensively studied. Several clinical studies have found slightly elevated serum MIF levels in patients with T2DM (150). Higher MIF levels were found in patients in pro-diabetic states spawning the theory of MIF level elevation preceding the onset of T2DM (58, 76, 88). These higher levels of MIF were shown to be a risk factor for coronary events in diabetics and especially to mediate myocardial damage (97).

Hence, MIF is one of the chemokines that directly relate to T2DM and risk for coronary disease. It has been suggested that it contributes to coronary disease development in diabetics indirectly through stimulation of the production of other cytokines. It also stimulates certain inflammatory adipocytokines promoting insulin resistance and creating a vicious circle (130).

4.2. GREMLIN-1 AS AN ENDOGENOUS ANTAGONIST OF MIF AND ITS ROLE IN ATHEROSCLEROSIS

Gremlin is a highly conserved 184 amino acid protein (20.7 kDa), which contains a cysteine-rich region and a cysteine knot motif, a structure shared by members of the TGF- β superfamily. Gremlin exists in both secreted and cell associated forms. This pattern of expression permits its binding to extracellular BMP-2, BMP-4 and BMP-7 and inhibition of smad-1, smad-5 and smad-8 signaling, when expressed on membranes of renal cells (165) or alternatively binding to the slit1 and slit2 receptor when expressed on monocyte membranes to act as negative modulator of monocyte chemotaxis (79). These are some of many possibly existing mechanisms of gremlin regulation of cellular behavior. High glucose levels have been showed to increase gremlin mRNA in pericytes and mesangial cells, implicating GREM1 in the pathogenesis of diabetic nephropathy and retinopathy (85, 100, 153).

The role of GREM1 in diabetes and coronary heart disease has not been adequately investigated. However, since it has been shown that it acts as an antagonist of MIF (109) it was interesting to investigate the correlation of

GREM1 and MIF levels in patients with IHD and diabetes. Regarding the role of GREM1 in atherosclerosis, gremlin-1 expression has been identified in humans at sites of arterial injury and has been shown that GREM1 inhibits MIF-induced foam cell formation and monocyte and macrophage adhesion on the atherosclerotic vessel wall, and reduces substantially plaque size and plaque foam cell content in ApoE^{-/-} mice in vivo (109).

It has also been shown that Gremlin1 induces a proinflammatory response in endothelial cells causing reactive oxygen species and cyclic adenosine monophosphate production and the upregulation of proinflammatory molecules involved in leukocyte extravasation like vascular cell adhesion molecule-1 (VCAM-1), results that suggest a cross-talk between angiogenesis and inflammation and demonstrate a role of gremlin in the proinflammatory/proangiogenic response (35).

4.3. EXPRESSION OF GREM1 AND MIF IN OUR GROUP OF PATIENTS WITH IHD

We managed to detect substantial levels of GREM1 and MIF proteins in lysates of platelet populations of healthy individuals, recognizing human platelet MIF as a 12.5 kDa protein and GREM1 as a band of approximately 20.7 kDa followed by a double band of approximately 25 kDa. Substantial levels of MIF and GREM1 were found through flow cytometry in platelet populations of patients with CAD.

Platelet bound MIF and MIF plasma levels correlated significantly in our study suggesting that platelets are probably a relevant source of plasmatic MIF and suggesting a cross talk between cells producing MIF and a complex regulation of its expression. The plasma levels of MIF were found to be independent of the white blood cell count; the same applied for GREM1 plasma levels. Furthermore GREM1 and MIF platelet bound levels were also independent from platelet

count in peripheral blood. Of note was that plasma levels of GREM1 correlated significantly with plasma levels of CRP.

We also managed to show that the levels of the two investigated proteins in human platelets correlate to each other statistically significantly with a p value of 0.0001. These findings are in accordance with a theory of variability of expression of these proteins depending on the inflammation status of the human organism and not the cell count itself. However, such findings suggest that platelets are an important vehicle for MIF and GREM1 through the cardiovascular system and that GREM1 and MIF production are regulated through the interaction of the two proteins.

Platelet-bound expression of MIF and GREM1 were found independent of platelet count and platelet reactivity status. High platelet reactivity can be considered a risk factor for post-PCI stent thrombosis and myocardial infarction, while patients with T2DM consist a high-risk group as they exhibit increased platelet reactivity (98, 133), but the clinical usefulness of platelet function testing and its role as an independent risk factor is still under question (48, 65, 86).

The expression and induction of CD62p indicating release reaction of α -granules and PAC-1 directed against activation-dependent epitopes on GPIIb/IIIa and GPVI expression correlated with the levels of platelet bound MIF and GREM1 proteins. P-selectin, a known recruitment and aggregation factor of platelets, has been found to correlate with the severity of acute coronary syndromes in patients with IHD, most probably through plaque disruption, rupture and thrombus formation (12, 19, 86). Increased expression of platelet glycoprotein VI (GPVI) correlated with increased MIF and GREM1 platelet expression. GPVI is a transmembranous glycoprotein that forms a complex with the Fc receptor at the platelet surface (111). Fc receptor expression correlates with collagen-induced aggregation and has been found increased in diabetics (28, 29). GPVI has been implicated in platelet-mediated arterial thrombosis (99), whereas it has been shown that platelets of patients with T2DM express GPVI

on their surface more than those of nondiabetics (25). The platelet binding of PAC-1, another monoclonal antibody that selectively interacts with activated GP IIb/IIIa, was also used as a platelet activation marker (86) and we found an up-regulation of expression correlates with up-regulated MIF and GREM1 platelet expression.

Such findings suggest a cross talk between activated leukocytes and platelets and regulation of platelet activation through inflammation and thus a role for GREM1 and MIF in atherothrombosis and acute myocardial infarctions.

In concordance with findings of previous studies plasma levels of MIF were found slightly elevated in patients with diabetes (76, 158), whereas the plasma levels of GREM1 in the same patient group were also found slightly elevated. When we compared levels of platelet bound MIF and GREM1 in diabetics and nondiabetics we found them significantly higher in diabetics in comparison to nondiabetics, while a more traditional marker for inflammation CRP, was also found increased. These results support the theory of platelet mediated GREM1 and MIF expression as important mediator in vascular inflammation in diabetics and the progression of CAD. Furthermore, levels of MIF and GREM1 expressed from platelets showed no correlation with the various therapy schemes, but only to the HbA1c levels, suggesting a direct correlation of MIF and GREM1 expression with the glucose levels and the progression of inflammatory mediated atherosclerosis in diabetics.

Only the levels of GREM1 correlated well with the maximum of creatinine kinase, while both the levels of GREM1 and MIF correlated with the most sensitive marker for cardiac injury at the moment, troponin. The higher the troponin levels were the lower the expression of MIF and GREM1 was. In patients with ACS expression of MIF and GREM1 was significantly lower than in patients with stable CHD. MIF and GREM1 levels also correlated with the ejection fraction of patients undergoing a cardiac ventriculography with down-regulation of MIF and GREM1 expression in patients with a left ventricular

dysfunction as consequence of a myocardial infarction. In those patients the plasma levels of GREM1 and MIF were found slightly higher. These findings highlight the connection of platelet bound MIF and GREM1 with the settings of ACS and the prognostic factors of CHD.

These finding could extend the role of GREM1 and MIF as markers for imminent myocardial ischemia in IHD and prognostic markers of the severity and the stadium of the disease. It could be suggested that ongoing ischemia causes platelets to release MIF and GREM1 produced in platelets to the adjacent tissues and into plasma, thus propagating atherothrombotic processes, myocardial fibrosis and post-infarction heart failure.

With the results of our current study are taken into account, one could conclude that platelets serve as carriers of MIF and GREM1 in patients with coronary artery disease and seem to release GREM1 and MIF during ACS. Patients at risk for a rapid progression of atherosclerosis, such as diabetic patients or patients with a high platelet activation status show a significant up-regulation of GREM1 and MIF. GREM1 and MIF might therefore be useful biomarkers in the clinical routine to assess individual risk. Future studies including follow-up measurements of MIF and GREM1 levels in CAD patients and studies with MACE endpoints are warranted to assess MIF and GREM1 as biomarker.

5. ZUSAMMENFASSUNG

Die Progression der Atherosklerose ist ein langjähriger Prozess und Diabetes mellitus stellt einen der wichtigsten Risikofaktoren der koronaren Herzkrankheit dar. Thrombozyten spielen eine wichtige Rolle bei der Hämostase, aber auch bei inflammatorischen Prozessen und bei der Atherosklerose sind sie wesentlich beteiligt, unter anderem, durch die zahlreiche Zytokine die sie beherbergen und die Bildung von Thromben auf rupturierten Plaques, was zum akuten Verschluss und damit zum akuten Myokardinfarkt führt. Makrophage migration inhibitory factor (MIF) ist ein ubiquitärer Mediator mit proinflammatorischer Wirkung. Seine Interaktion mit GREM1 in der Atherosklerose in APO-Mäusen wurde durch unsere Gruppe beschrieben und die Rolle von GREM1 als endogener Inhibitor von MIF erläutert.

Um die Expression, Funktion und Interaktion von MIF und GREM1 in der Atherogenese zu analysieren, untersuchten wir in 300 KHK-Patienten die Expression von MIF und GREM1 von Thrombozyten mittels Western Blotting und Durchflusszytometrie und deren Plasma-Spiegel durch ELISA. Die MIF und GREM1 Expression war unabhängig von Thrombozytenzahl, Leukozytenzahl und begleitender medikamentöser Therapie, inklusive Thrombozytenaggregationshemmer. Bei Diabetikern waren Thrombozytenaktivierungsmarker signifikant höher und korrelierten sich mit der thrombozytären Expression von MIF und GREM1. Zudem waren bei Diabetikern die MIF- und GREM1-Konzentration im Serum höher und die thrombozytenassoziierte Expression von MIF und GREM1 korrelierten signifikant mit dem HbA1c-Wert, mit dem Troponin und mit der Ejektionsfraktion.

Unsere Ergebnisse lassen darauf schließen, dass Thrombozyten als Quelle von MIF und GREM1 dienen, die als Mediatoren der vaskulären Inflammation bei Diabetikern agieren. Diese Erkenntnisse bringen wichtige Informationen über mögliche Interaktionen von MIF und GREM1 und die damit verbundene mögliche Entwicklung spezifischer Inhibitoren, womit neue Therapieansätze in der Behandlung der vaskulären Komplikationen des Diabetes mellitus geschaffen werden können.

6. REFERENCES

1. World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. *JAMA : the journal of the American Medical Association*. 1997;277(11):925-6.
2. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. *Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe*. *Lancet*. 1999;354(9179):617-21.
3. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice. *J Postgrad Med*. 2001;47(3):199-203.
4. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the member states relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. *Med Etika Bioet*. 2002;9(1-2):12-9.
5. Addison D, Aguilar D. Diabetes and cardiovascular disease: the potential benefit of incretin-based therapies. *Current atherosclerosis reports*. 2011;13(2):115-22.
6. Ambrose JA, Tannenbaum MA, Alexopoulos D, Hjerdahl-Monsen CE, Leavy J, Weiss M, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. *Journal of the American College of Cardiology*. 1988;12(1):56-62.
7. American Diabetes A. Diagnosis and classification of diabetes mellitus. *Diabetes care*. 2012;35 Suppl 1:S64-71.
8. Arca M, Montali A, Valiante S, Campagna F, Pigna G, Paoletti V, et al. Usefulness of atherogenic dyslipidemia for predicting cardiovascular risk in patients with angiographically defined coronary artery disease. *The American journal of cardiology*. 2007;100(10):1511-6.
9. Asare Y, Schmitt M, Bernhagen J. The vascular biology of macrophage migration inhibitory factor (MIF). Expression and effects in inflammation, atherogenesis and angiogenesis. *Thrombosis and haemostasis*. 2013;109(3):391-8.
10. Atsumi T, Cho YR, Leng L, McDonald C, Yu T, Danton C, et al. The proinflammatory cytokine macrophage migration inhibitory factor regulates glucose metabolism during systemic inflammation. *Journal of immunology*. 2007;179(8):5399-406.
11. Aukrust P, Halvorsen B, Ueland T, Michelsen AE, Skjelland M, Gullestad L, et al. Activated platelets and atherosclerosis. Expert review of cardiovascular therapy. 2010;8(9):1297-307.
12. Ault KA, Cannon CP, Mitchell J, McCahan J, Tracy RP, Novotny WF, et al. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. *Thrombolysis in Myocardial Infarction*. *Journal of the American College of Cardiology*. 1999;33(3):634-9.
13. Authors/Task Force M, Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European

Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). *European heart journal*. 2013;34(39):3035-87.

14. Badrnya S, Schrottmaier WC, Kral JB, Yaiw KC, Volf I, Schabbauer G, et al. Platelets mediate oxidized low-density lipoprotein-induced monocyte extravasation and foam cell formation. *Arteriosclerosis, thrombosis, and vascular biology*. 2014;34(3):571-80.

15. Bakker W, Eringa EC, Sipkema P, van Hinsbergh VW. Endothelial dysfunction and diabetes: roles of hyperglycemia, impaired insulin signaling and obesity. *Cell and tissue research*. 2009;335(1):165-89.

16. Bernhagen J, Calandra T, Cerami A, Bucala R. Macrophage migration inhibitory factor is a neuroendocrine mediator of endotoxaemia. *Trends in microbiology*. 1994;2(6):198-201.

17. Bernhagen J, Calandra T, Mitchell RA, Martin SB, Tracey KJ, Voelter W, et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. *Nature*. 1993;365(6448):756-9.

18. Bernhagen J, Mitchell RA, Calandra T, Voelter W, Cerami A, Bucala R. Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). *Biochemistry*. 1994;33(47):14144-55.

19. Blann AD, Lip GY. Hypothesis: is soluble P-selectin a new marker of platelet activation? *Atherosclerosis*. 1997;128(2):135-8.

20. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. Optimal medical therapy with or without PCI for stable coronary disease. *The New England journal of medicine*. 2007;356(15):1503-16.

21. Bombeli T, Schwartz BR, Harlan JM. Adhesion of activated platelets to endothelial cells: evidence for a GPIIb/IIIa-dependent bridging mechanism and novel roles for endothelial intercellular adhesion molecule 1 (ICAM-1), alpha5beta3 integrin, and GPIbalpha. *The Journal of experimental medicine*. 1998;187(3):329-39.

22. Burger-Kentischer A, Gobel H, Kleemann R, Zerneck A, Bucala R, Leng L, et al. Reduction of the aortic inflammatory response in spontaneous atherosclerosis by blockade of macrophage migration inhibitory factor (MIF). *Atherosclerosis*. 2006;184(1):28-38.

23. Burger-Kentischer A, Goebel H, Seiler R, Fraedrich G, Schaefer HE, Dimmeler S, et al. Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis. *Circulation*. 2002;105(13):1561-6.

24. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. *Circulation*. 2007;115(1):114-26.

25. Cabeza N, Li Z, Schulz C, Kremmer E, Massberg S, Bultmann A, et al. Surface expression of collagen receptor Fc receptor-gamma/glycoprotein VI is enhanced on platelets in type 2 diabetes and mediates release of CD40 ligand and activation of endothelial cells. *Diabetes*. 2004;53(8):2117-21.

26. Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, et al. MIF as a glucocorticoid-induced modulator of cytokine production. *Nature*. 1995;377(6544):68-71.

27. Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. *Nature reviews Immunology*. 2003;3(10):791-800.
28. Calverley DC, Brass E, Hacker MR, Tsao-Wei DD, Espina BM, Pullarkat VA, et al. Potential role of platelet FcγRIIA in collagen-mediated platelet activation associated with atherothrombosis. *Atherosclerosis*. 2002;164(2):261-7.
29. Calverley DC, Hacker MR, Loda KA, Brass E, Buchanan TA, Tsao-Wei DD, et al. Increased platelet Fc receptor expression as a potential contributing cause of platelet hypersensitivity to collagen in diabetes mellitus. *British journal of haematology*. 2003;121(1):139-42.
30. Casas JP, Shah T, Cooper J, Hawe E, McMahon AD, Gaffney D, et al. Insight into the nature of the CRP-coronary event association using Mendelian randomization. *International journal of epidemiology*. 2006;35(4):922-31.
31. Chang K, Weiss D, Suo J, Vega JD, Giddens D, Taylor WR, et al. Bone morphogenic protein antagonists are coexpressed with bone morphogenic protein 4 in endothelial cells exposed to unstable flow in vitro in mouse aortas and in human coronary arteries: role of bone morphogenic protein antagonists in inflammation and atherosclerosis. *Circulation*. 2007;116(11):1258-66.
32. Chatzizisis YS, Coskun AU, Jonas M, Edelman ER, Feldman CL, Stone PH. Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior. *Journal of the American College of Cardiology*. 2007;49(25):2379-93.
33. Chen B, Blair DG, Plisov S, Vasiliev G, Perantoni AO, Chen Q, et al. Cutting edge: bone morphogenetic protein antagonists Dm/Gremlin and Dan interact with Slits and act as negative regulators of monocyte chemotaxis. *Journal of immunology*. 2004;173(10):5914-7.
34. Chen Z, Sakuma M, Zago AC, Zhang X, Shi C, Leng L, et al. Evidence for a role of macrophage migration inhibitory factor in vascular disease. *Arteriosclerosis, thrombosis, and vascular biology*. 2004;24(4):709-14.
35. Corsini M, Moroni E, Ravelli C, Andres G, Grillo E, Ali IH, et al. Cyclic adenosine monophosphate-response element-binding protein mediates the proangiogenic or proinflammatory activity of gremlin. *Arteriosclerosis, thrombosis, and vascular biology*. 2014;34(1):136-45.
36. Cosentino F, Hishikawa K, Katusic ZS, Luscher TF. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. *Circulation*. 1997;96(1):25-8.
37. Critchley JA, Capewell S. WITHDRAWN: Smoking cessation for the secondary prevention of coronary heart disease. *The Cochrane database of systematic reviews*. 2012;2:CD003041.
38. Danaei G, Lawes CM, Vander Hoorn S, Murray CJ, Ezzati M. Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment. *Lancet*. 2006;368(9548):1651-9.
39. Davies MJ, Thomas AC, Knapman PA, Hangartner JR. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. *Circulation*. 1986;73(3):418-27.

40. De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. *The New England journal of medicine*. 2012;367(11):991-1001.
41. Decode Study Group EDEG. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? *Diabetes care*. 2003;26(3):688-96.
42. DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. *Diabetologia*. 2010;53(7):1270-87.
43. Degryse B, de Virgilio M. The nuclear protein HMGB1, a new kind of chemokine? *FEBS letters*. 2003;553(1-2):11-7.
44. Detre K, Murphy ML, Hultgren H. Effect of coronary bypass surgery on longevity in high and low risk patients. Report from the V.A. Cooperative Coronary Surgery Study. *Lancet*. 1977;2(8051):1243-5.
45. Diecke S, Quiroga-Negreira A, Redmer T, Besser D. FGF2 signaling in mouse embryonic fibroblasts is crucial for self-renewal of embryonic stem cells. *Cells, tissues, organs*. 2008;188(1-2):52-61.
46. Dolan V, Murphy M, Sadlier D, Lappin D, Doran P, Godson C, et al. Expression of gremlin, a bone morphogenetic protein antagonist, in human diabetic nephropathy. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2005;45(6):1034-9.
47. Donnelly SC, Haslett C, Reid PT, Grant IS, Wallace WA, Metz CN, et al. Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. *Nature medicine*. 1997;3(3):320-3.
48. Droppa M, Tschernow D, Muller KA, Tavlaki E, Karathanos A, Stimpfle F, et al. Evaluation of clinical risk factors to predict high on-treatment platelet reactivity and outcome in patients with stable coronary artery disease (PREDICT-STABLE). *PLoS one*. 2015;10(3):e0121620.
49. Emerging Risk Factors C, Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. *The New England journal of medicine*. 2012;367(14):1310-20.
50. Emerging Risk Factors C, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. *Lancet*. 2010;375(9733):2215-22.
51. Emonts M, Sweep FC, Grebenchtchikov N, Geurts-Moespot A, Knaup M, Chanson AL, et al. Association between high levels of blood macrophage migration inhibitory factor, inappropriate adrenal response, and early death in patients with severe sepsis. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2007;44(10):1321-8.
52. Estruch R, Ros E, Salas-Salvado J, Covas MI, Corella D, Aros F, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. *The New England journal of medicine*. 2013;368(14):1279-90.
53. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. *Circulation*. 1985;71(4):699-708.

54. Falk E, Nakano M, Bentzon JF, Finn AV, Virmani R. Update on acute coronary syndromes: the pathologists' view. *European heart journal*. 2013;34(10):719-28.
55. Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, et al. Strategies for multivessel revascularization in patients with diabetes. *The New England journal of medicine*. 2012;367(25):2375-84.
56. Ferrante G, Nakano M, Prati F, Niccoli G, Mallus MT, Ramazzotti V, et al. High levels of systemic myeloperoxidase are associated with coronary plaque erosion in patients with acute coronary syndromes: a clinicopathological study. *Circulation*. 2010;122(24):2505-13.
57. Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R. Concept of vulnerable/unstable plaque. *Arteriosclerosis, thrombosis, and vascular biology*. 2010;30(7):1282-92.
58. Finucane OM, Reynolds CM, McGillicuddy FC, Roche HM. Insights into the role of macrophage migration inhibitory factor in obesity and insulin resistance. *The Proceedings of the Nutrition Society*. 2012;71(4):622-33.
59. Flammer AJ, Anderson T, Celermajer DS, Creager MA, Deanfield J, Ganz P, et al. The assessment of endothelial function: from research into clinical practice. *Circulation*. 2012;126(6):753-67.
60. Fleg JL, Stone GW, Fayad ZA, Granada JF, Hatsukami TS, Kolodgie FD, et al. Detection of high-risk atherosclerotic plaque: report of the NHLBI Working Group on current status and future directions. *JACC Cardiovascular imaging*. 2012;5(9):941-55.
61. Fox CS, Coady S, Sorlie PD, D'Agostino RB, Sr., Pencina MJ, Vasan RS, et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. *Circulation*. 2007;115(12):1544-50.
62. Fruchart JC, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. *The American journal of cardiology*. 2008;102(10 Suppl):1K-34K.
63. Gao XM, Liu Y, White D, Su Y, Drew BG, Bruce CR, et al. Deletion of macrophage migration inhibitory factor protects the heart from severe ischemia-reperfusion injury: a predominant role of anti-inflammation. *Journal of molecular and cellular cardiology*. 2011;50(6):991-9.
64. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. *Annual review of immunology*. 2005;23:337-66.
65. Geisler T, Booth J, Tavlaki E, Karathanos A, Muller K, Droppa M, et al. High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel. *PloS one*. 2015;10(8):e0135037.
66. Gimbrone MA, Jr. Endothelial dysfunction, hemodynamic forces, and atherosclerosis. *Thrombosis and haemostasis*. 1999;82(2):722-6.
67. Giorgino F, Leonardini A, Laviola L. Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials. *Annals of the New York Academy of Sciences*. 2013;1281:36-50.

68. Glaser R, Selzer F, Faxon DP, Laskey WK, Cohen HA, Slater J, et al. Clinical progression of incidental, asymptomatic lesions discovered during culprit vessel coronary intervention. *Circulation*. 2005;111(2):143-9.
69. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics--2013 update: a report from the American Heart Association. *Circulation*. 2013;127(1):e6-e245.
70. Grant PJ. Diabetes mellitus as a prothrombotic condition. *Journal of internal medicine*. 2007;262(2):157-72.
71. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2010;122(25):2748-64.
72. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). *European heart journal*. 2011;32(23):2999-3054.
73. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. *The New England journal of medicine*. 2005;352(16):1685-95.
74. Hartvigsen K, Chou MY, Hansen LF, Shaw PX, Tsimikas S, Binder CJ, et al. The role of innate immunity in atherogenesis. *Journal of lipid research*. 2009;50 Suppl:S388-93.
75. Herder C, Baumert J, Zierer A, Roden M, Meisinger C, Karakas M, et al. Immunological and cardiometabolic risk factors in the prediction of type 2 diabetes and coronary events: MONICA/KORA Augsburg case-cohort study. *PloS one*. 2011;6(6):e19852.
76. Herder C, Kolb H, Koenig W, Haastert B, Muller-Scholze S, Rathmann W, et al. Association of systemic concentrations of macrophage migration inhibitory factor with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg, Survey 4 (KORA S4). *Diabetes care*. 2006;29(2):368-71.
77. Herder C, Peltonen M, Koenig W, Kraft I, Muller-Scholze S, Martin S, et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. *Diabetes*. 2006;55(8):2340-6.
78. Hossain P, Kavar B, El Nahas M. Obesity and diabetes in the developing world--a growing challenge. *The New England journal of medicine*. 2007;356(3):213-5.
79. Huang H, Huang H, Li Y, Liu M, Shi Y, Chi Y, et al. Gremlin induces cell proliferation and extra cellular matrix accumulation in mouse mesangial cells exposed to high glucose via the ERK1/2 pathway. *BMC nephrology*. 2013;14:33.
80. Investigators T. Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial. *Lancet*. 2001;358(9286):951-7.

81. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetologia*. 2012;55(6):1577-96.
82. Janeway CA, Jr. Approaching the asymptote? Evolution and revolution in immunology. *Cold Spring Harbor symposia on quantitative biology*. 1989;54 Pt 1:1-13.
83. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. *Circulation*. 2001;103(15):1933-5.
84. Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE, Jr., et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Journal of the American College of Cardiology*. 2012;60(7):645-81.
85. Kane R, Stevenson L, Godson C, Stitt AW, O'Brien C. Gremlin gene expression in bovine retinal pericytes exposed to elevated glucose. *The British journal of ophthalmology*. 2005;89(12):1638-42.
86. Karathanos A, Geisler T. Monitoring aspirin and clopidogrel response: testing controversies and recommendations. *Mol Diagn Ther*. 2013;17(3):123-37.
87. Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk). *Bmj*. 2001;322(7277):15-8.
88. Kleemann R, Bucala R. Macrophage migration inhibitory factor: critical role in obesity, insulin resistance, and associated comorbidities. *Mediators of inflammation*. 2010;2010:610479.
89. Kleemann R, Hausser A, Geiger G, Mischke R, Burger-Kentischer A, Flieger O, et al. Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. *Nature*. 2000;408(6809):211-6.
90. Lee M, Saver JL, Towfighi A, Chow J, Ovbiagele B. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. *Atherosclerosis*. 2011;217(2):492-8.
91. Libby P. Inflammation in atherosclerosis. *Nature*. 2002;420(6917):868-74.
92. Libby P, Ridker PM, Hansson GK, Leducq Transatlantic Network on A. Inflammation in atherosclerosis: from pathophysiology to practice. *Journal of the American College of Cardiology*. 2009;54(23):2129-38.
93. Lin SG, Yu XY, Chen YX, Huang XR, Metz C, Bucala R, et al. De novo expression of macrophage migration inhibitory factor in atherogenesis in rabbits. *Circulation research*. 2000;87(12):1202-8.
94. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuffi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid a protein in

- severe unstable angina. *The New England journal of medicine*. 1994;331(7):417-24.
95. Ltd RDI. Multiplate® analyzer: Comprehensive reagent menu. In: Roche, editor. Rotkreuz, Switzerland: Roche; 2013.
 96. Lu MM, Yang H, Zhang L, Shu W, Blair DG, Morrissey EE. The bone morphogenic protein antagonist gremlin regulates proximal-distal patterning of the lung. *Developmental dynamics : an official publication of the American Association of Anatomists*. 2001;222(4):667-80.
 97. Makino A, Nakamura T, Hirano M, Kitta Y, Sano K, Kobayashi T, et al. High plasma levels of macrophage migration inhibitory factor are associated with adverse long-term outcome in patients with stable coronary artery disease and impaired glucose tolerance or type 2 diabetes mellitus. *Atherosclerosis*. 2010;213(2):573-8.
 98. Mandal S, Sarode R, Dash S, Dash RJ. Hyperaggregation of platelets detected by whole blood platelet aggregometry in newly diagnosed noninsulin-dependent diabetes mellitus. *American journal of clinical pathology*. 1993;100(2):103-7.
 99. Massberg S, Gawaz M, Gruner S, Schulte V, Konrad I, Zohlnhofer D, et al. A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo. *The Journal of experimental medicine*. 2003;197(1):41-9.
 100. McMahon R, Murphy M, Clarkson M, Taal M, Mackenzie HS, Godson C, et al. IHG-2, a mesangial cell gene induced by high glucose, is human gremlin. Regulation by extracellular glucose concentration, cyclic mechanical strain, and transforming growth factor-beta1. *The Journal of biological chemistry*. 2000;275(14):9901-4.
 101. Meyer A, Wang W, Qu J, Croft L, Degen JL, Coller BS, et al. Platelet TGF-beta1 contributions to plasma TGF-beta1, cardiac fibrosis, and systolic dysfunction in a mouse model of pressure overload. *Blood*. 2012;119(4):1064-74.
 102. Meyers DG, Neuberger JS, He J. Cardiovascular effect of bans on smoking in public places: a systematic review and meta-analysis. *Journal of the American College of Cardiology*. 2009;54(14):1249-55.
 103. Michos O, Goncalves A, Lopez-Rios J, Tiecke E, Naillat F, Beier K, et al. Reduction of BMP4 activity by gremlin 1 enables ureteric bud outgrowth and GDNF/WNT11 feedback signalling during kidney branching morphogenesis. *Development*. 2007;134(13):2397-405.
 104. Mikayama T, Nakano T, Gomi H, Nakagawa Y, Liu YC, Sato M, et al. Molecular cloning and functional expression of a cDNA encoding glycosylation-inhibiting factor. *Proceedings of the National Academy of Sciences of the United States of America*. 1993;90(21):10056-60.
 105. Miller EJ, Li J, Leng L, McDonald C, Atsumi T, Bucala R, et al. Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. *Nature*. 2008;451(7178):578-82.
 106. Mitola S, Ravelli C, Moroni E, Salvi V, Leali D, Ballmer-Hofer K, et al. Gremlin is a novel agonist of the major proangiogenic receptor VEGFR2. *Blood*. 2010;116(18):3677-80.
 107. Morrow DA, de Lemos JA, Sabatine MS, Wiviott SD, Blazing MA, Shui A, et al. Clinical relevance of C-reactive protein during follow-up of patients with

- acute coronary syndromes in the Aggrastat-to-Zocor Trial. *Circulation*. 2006;114(4):281-8.
108. Muller, II, Muller KA, Karathanos A, Schonleber H, Rath D, Vogel S, et al. Impact of counterbalance between macrophage migration inhibitory factor and its inhibitor Gremlin-1 in patients with coronary artery disease. *Atherosclerosis*. 2014;237(2):426-32.
109. Muller I, Schonberger T, Schneider M, Borst O, Ziegler M, Seizer P, et al. Gremlin-1 is an inhibitor of macrophage migration inhibitory factor and attenuates atherosclerotic plaque growth in ApoE^{-/-} Mice. *The Journal of biological chemistry*. 2013;288(44):31635-45.
110. Muller II, Muller KA, Schonleber H, Karathanos A, Schneider M, Jorbenadze R, et al. Macrophage migration inhibitory factor is enhanced in acute coronary syndromes and is associated with the inflammatory response. *PLoS one*. 2012;7(6):e38376.
111. Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? *Blood*. 2003;102(2):449-61.
112. Ning F, Tuomilehto J, Pyorala K, Onat A, Soderberg S, Qiao Q, et al. Cardiovascular disease mortality in Europeans in relation to fasting and 2-h plasma glucose levels within a normoglycemic range. *Diabetes care*. 2010;33(10):2211-6.
113. Organisation WH. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Geneva, Switzerland: World Health Organization, Surveillance DoND; 1999 Contract No.: 99.2.
114. Organization WH. Geneva, Switzerland: WHO, 2013 November 2013. Report No.
115. Organization WH. Diabetes: Fact sheet N° 312. Geneva, Switzerland: World Health Organization, 2013 October 2013. Report No.
116. Organization WH. GLOBAL HEALTH ESTIMATES SUMMARY TABLES: DEATHS BY CAUSE, AGE AND SEX. Geneva, Switzerland: WHO, 2013 June 2013. Report No.
117. Organization WH. GLOBAL HEALTH ESTIMATES SUMMARY TABLES: Projection. Geneva, Switzerland: WHO, 2013 June 2013. Report No.
118. Pan JH, Sukhova GK, Yang JT, Wang B, Xie T, Fu H, et al. Macrophage migration inhibitory factor deficiency impairs atherosclerosis in low-density lipoprotein receptor-deficient mice. *Circulation*. 2004;109(25):3149-53.
119. Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. *European heart journal*. 2013;34(31):2436-43.
120. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. *The Journal of clinical investigation*. 2003;111(12):1805-12.
121. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). *European heart journal*. 2012;33(13):1635-701.
122. Pietila KO, Harmoinen AP, Jokiniitty J, Pasternack AI. Serum C-reactive protein concentration in acute myocardial infarction and its relationship to

mortality during 24 months of follow-up in patients under thrombolytic treatment. *European heart journal*. 1996;17(9):1345-9.

123. Poon IK, Hulett MD, Parish CR. Molecular mechanisms of late apoptotic/necrotic cell clearance. *Cell death and differentiation*. 2010;17(3):381-97.

124. Prevention CfDCa. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S.: Department of Health and Human Services, Centers for Disease Control and Prevention, 2011 2011. Report No.

125. Ridker PM. C-reactive protein: eighty years from discovery to emergence as a major risk marker for cardiovascular disease. *Clinical chemistry*. 2009;55(2):209-15.

126. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. *JAMA : the journal of the American Medical Association*. 2007;297(6):611-9.

127. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr., Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *The New England journal of medicine*. 2008;359(21):2195-207.

128. Romeo GR, Lee J, Shoelson SE. Metabolic syndrome, insulin resistance, and roles of inflammation--mechanisms and therapeutic targets. *Arteriosclerosis, thrombosis, and vascular biology*. 2012;32(8):1771-6.

129. Ross R. Atherosclerosis--an inflammatory disease. *The New England journal of medicine*. 1999;340(2):115-26.

130. Sanchez-Zamora YI, Rodriguez-Sosa M. The role of MIF in type 1 and type 2 diabetes mellitus. *Journal of diabetes research*. 2014;2014:804519.

131. Schaar JA, Muller JE, Falk E, Virmani R, Fuster V, Serruys PW, et al. Terminology for high-risk and vulnerable coronary artery plaques. Report of a meeting on the vulnerable plaque, June 17 and 18, 2003, Santorini, Greece. *European heart journal*. 2004;25(12):1077-82.

132. Schmeisser A, Marquetant R, Illmer T, Graffy C, Garlachs CD, Bockler D, et al. The expression of macrophage migration inhibitory factor 1alpha (MIF 1alpha) in human atherosclerotic plaques is induced by different proatherogenic stimuli and associated with plaque instability. *Atherosclerosis*. 2005;178(1):83-94.

133. Schneider DJ. Factors contributing to increased platelet reactivity in people with diabetes. *Diabetes care*. 2009;32(4):525-7.

134. Schober A, Bernhagen J, Thiele M, Zeiffer U, Knarren S, Roller M, et al. Stabilization of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient mice. *Circulation*. 2004;109(3):380-5.

135. Shi W, Zhao J, Anderson KD, Warburton D. Gremlin negatively modulates BMP-4 induction of embryonic mouse lung branching morphogenesis. *American journal of physiology Lung cellular and molecular physiology*. 2001;280(5):L1030-9.

136. Shimizu T, Nishihira J, Watanabe H, Abe R, Honda A, Ishibashi T, et al. Macrophage migration inhibitory factor is induced by thrombin and factor Xa in endothelial cells. *The Journal of biological chemistry*. 2004;279(14):13729-37.
137. Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schomig A, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. *Journal of the American College of Cardiology*. 2009;53(10):849-56.
138. Sibbing D, Morath T, Braun S, Stegherr J, Mehilli J, Vogt W, et al. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. *Thrombosis and haemostasis*. 2010;103(1):151-9.
139. Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, et al. A prospective natural-history study of coronary atherosclerosis. *The New England journal of medicine*. 2011;364(3):226-35.
140. Sun J, Zhuang FF, Mullersman JE, Chen H, Robertson EJ, Warburton D, et al. BMP4 activation and secretion are negatively regulated by an intracellular gremlin-BMP4 interaction. *The Journal of biological chemistry*. 2006;281(39):29349-56.
141. Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. *Journal of the American College of Cardiology*. 2013;62(24):2261-73.
142. Task Force for D, Treatment of Non STSEACSoESoC, Bassand JP, Hamm CW, Ardissino D, Boersma E, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. *European heart journal*. 2007;28(13):1598-660.
143. Task Force M, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. *European heart journal*. 2013;34(38):2949-3003.
144. Task Force on the management of STsegmentESoC, Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *European heart journal*. 2012;33(20):2569-619.
145. Tea L. Reversal of Risk After Quitting Smoking. *IARC Handbooks of Cancer Prevention, Tobacco Control*. 11: IARC, World Health Organization; 2007. p. 366.
146. Tennent GA, Hutchinson WL, Kahan MC, Hirschfield GM, Gallimore JR, Lewin J, et al. Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE^{-/-} mice. *Atherosclerosis*. 2008;196(1):248-55.
147. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. *European heart journal*. 2012;33(20):2551-67.
148. Topol LZ, Bardot B, Zhang Q, Resau J, Huillard E, Marx M, et al. Biosynthesis, post-translation modification, and functional characterization of Drm/Gremlin. *The Journal of biological chemistry*. 2000;275(12):8785-93.

149. Topol LZ, Marx M, Laugier D, Bogdanova NN, Boubnov NV, Clausen PA, et al. Identification of *drm*, a novel gene whose expression is suppressed in transformed cells and which can inhibit growth of normal but not transformed cells in culture. *Molecular and cellular biology*. 1997;17(8):4801-10.
150. Toso C, Emamaullee JA, Merani S, Shapiro AM. The role of macrophage migration inhibitory factor on glucose metabolism and diabetes. *Diabetologia*. 2008;51(11):1937-46.
151. Verma S, Farkouh ME, Yanagawa B, Fitchett DH, Ahsan MR, Ruel M, et al. Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: a meta-analysis of randomised controlled trials. *The lancet Diabetes & endocrinology*. 2013;1(4):317-28.
152. Verschuren L, Kooistra T, Bernhagen J, Voshol PJ, Ouwens DM, van Erk M, et al. MIF deficiency reduces chronic inflammation in white adipose tissue and impairs the development of insulin resistance, glucose intolerance, and associated atherosclerotic disease. *Circulation research*. 2009;105(1):99-107.
153. Walsh DW, Roxburgh SA, McGettigan P, Berthier CC, Higgins DG, Kretzler M, et al. Co-regulation of Gremlin and Notch signalling in diabetic nephropathy. *Biochimica et biophysica acta*. 2008;1782(1):10-21.
154. Wang H, Zhu S, Zhou R, Li W, Sama AE. Therapeutic potential of HMGB1-targeting agents in sepsis. *Expert reviews in molecular medicine*. 2008;10:e32.
155. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes care*. 2004;27(5):1047-53.
156. William H. Some account of a disorder of the breast. *Medical Transactions*. 1772(2):59-67.
157. Wilson PW, Pencina M, Jacques P, Selhub J, D'Agostino R, Sr., O'Donnell CJ. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. *Circulation Cardiovascular quality and outcomes*. 2008;1(2):92-7.
158. Yabunaka N, Nishihira J, Mizue Y, Tsuji M, Kumagai M, Ohtsuka Y, et al. Elevated serum content of macrophage migration inhibitory factor in patients with type 2 diabetes. *Diabetes care*. 2000;23(2):256-8.
159. Yang N, Nikolic-Paterson DJ, Ng YY, Mu W, Metz C, Bacher M, et al. Reversal of established rat crescentic glomerulonephritis by blockade of macrophage migration inhibitory factor (MIF): potential role of MIF in regulating glucocorticoid production. *Molecular medicine*. 1998;4(6):413-24.
160. Yu XY, Chen HM, Liang JL, Lin QX, Tan HH, Fu YH, et al. Hyperglycemic myocardial damage is mediated by proinflammatory cytokine: macrophage migration inhibitory factor. *PloS one*. 2011;6(1):e16239.
161. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. *The New England journal of medicine*. 2001;345(7):494-502.
162. Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. *Lancet*. 1994;344(8922):563-70.

163. Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. *The Journal of clinical investigation*. 1996;98(4):894-8.
164. Zhang H, Dellsperger KC, Zhang C. The link between metabolic abnormalities and endothelial dysfunction in type 2 diabetes: an update. *Basic research in cardiology*. 2012;107(1):237.
165. Zhang Y, Zhang Q. Bone morphogenetic protein-7 and Gremlin: New emerging therapeutic targets for diabetic nephropathy. *Biochemical and biophysical research communications*. 2009;383(1):1-3.

7. PUBLICATIONS

1. Muller, II, Muller KA, Schonleber H, Karathanos A, Schneider M, Jorbenadze R, et al. Macrophage migration inhibitory factor is enhanced in acute coronary syndromes and is associated with the inflammatory response. *PLoS One*. 2012;7(6):e38376.
2. Tolios A, Gatidis S, Munzer P, Liu G, Towhid ST, Karathanos A, et al. Increased platelet Ca²⁺ channel Orai1 expression upon platelet activation and in patients with acute myocardial infarction. *Thromb Haemost*. 2013;110(2):386-9.
3. Karathanos A, Geisler T. Monitoring aspirin and clopidogrel response: testing controversies and recommendations. *Mol Diagn Ther*. 2013;17(3):123-37.
4. Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. *N Engl J Med*. 2013;368(14):1303-13.
5. Rath D, Chatterjee M, Muller I, Muller K, Bockmann C, Droppa M, et al. Platelet expression of transforming growth factor beta 1 is enhanced and associated with cardiovascular prognosis in patients with acute coronary syndrome. *Atherosclerosis*. 2014;237(2):754-9.
6. Muller, II, Muller KA, Karathanos A, Schonleber H, Rath D, Vogel S, et al. Impact of counterbalance between macrophage migration inhibitory factor and its inhibitor Gremlin-1 in patients with coronary artery disease. *Atherosclerosis*. 2014;237(2):426-32.
7. Stimpfle F, Karathanos A, Droppa M, Metzger J, Rath D, Muller K, et al. Impact of point-of-care testing for CYP2C19 on platelet inhibition in patients with acute coronary syndrome and early dual antiplatelet therapy in the emergency setting. *Thromb Res*. 2014;134(1):105-10.
8. Muller KA, Karathanos A, Tavlaki E, Stimpfle F, Meissner M, Bigalke B, et al. Combination of high on-treatment platelet aggregation and low deaggregation better predicts long-term cardiovascular events in PCI patients under dual antiplatelet therapy. *Platelets*. 2014;25(6):439-46.
9. Geisler T, Muller K, Karathanos A, Bocksch W, Gawaz M, Deliargyris E, et al. Impact of antithrombotic treatment on short-term outcomes after percutaneous coronary intervention for left main disease: a pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trials. *EuroIntervention*. 2014;10(1):97-104.
10. Geisler T, Booth J, Tavlaki E, Karathanos A, Muller K, Droppa M, et al. High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel. *PLoS One*. 2015;10(8):e0135037.
11. Droppa M, Karathanos A, Gawaz M, Geisler T. Individualised dual antiplatelet therapy in a patient with short bowel syndrome after acute myocardial infarction with coronary artery stenting. *BMJ Case Rep*. 2015;2015.
12. Droppa M, Tschernow D, Muller KA, Tavlaki E, Karathanos A, Stimpfle F, et al. Evaluation of clinical risk factors to predict high on-treatment platelet

reactivity and outcome in patients with stable coronary artery disease (PREDICT-STABLE). PLoS One. 2015;10(3):e0121620.

13. Patzelt J, Mueller KA, Breuning S, Karathanos A, Schleicher R, Seizer P, et al. Expression of anaphylatoxin receptors on platelets in patients with coronary heart disease. *Atherosclerosis*. 2015;238(2):289-95.

Posters and oral presentations

DGK-Jahrestagung

2012 Clin Res Cardiol. 2012 Apr;101 Suppl 1:1. Impact factor (2014): 4.56

I.I. Müller, A. Karathanos, M. Schneider, K. A. L. Müller, H. Schönleber, P. Seizer, M. Gawaz, T. Geisler (2012) "Macrophage migration inhibitory factor" (MIF) is carried by platelets of patients with stable and unstable angina pectoris and its amount correlates with the stability of coronary artery disease. Oral presentation (78. Jahrestagung)

I.I. Müller, M. Schneider, A. Karathanos, K. A. L. Müller, H. Schönleber, P. Seizer, M. Gawaz, T. Geisler (2012) The pro-angiogenic BMP-antagonists Gremlin 1 and -2 are expressed in platelets of patients with acute coronary syndrome and correlate with platelet activation. Poster (78. Jahrestagung)

P. Seizer, K. Mueller, I. Mueller, A. Karathanos, B. Bigalke, M. Gawaz, T. Geisler, A. May (2012) Platelet-bound Cyclophilin A in patients with acute coronary syndrome. Poster (78. Jahrestagung)

T. Geisler, A. Karathanos, K. Mueller, I. Mueller, F. Stimpfle, B. Bigalke, P. Seizer, M. Gawaz (2012) Individualized Anti-platelet therapy guided by genotype analysis in patients with acute coronary syndromes. Oral presentation (78. Jahrestagung)

2013 Clin Res Cardiol. 2013 Apr;102 Suppl 1:1. Impact factor (2014): 4.56

A. Kiliyas, P. Berlitz, A. Karathanos, R. J. Sauter, P. Seizer, K. A. L. Müller, C. S. Zürn, T. Geisler, M. Gawaz, J. Schreieck. Event-triggered anticoagulation of patients after catheter ablation of atrial fibrillation guided by implantable cardiac monitors – early experience. Oral presentation (79. Jahrestagung)

I. I. Müller, K. A. L. Müller, A. Karathanos, H. Schönleber, C. Chakkalakal, M. Haas, D. Eppler, M. Schneider, M. Gawaz, T. Geisler. The MIF-antagonist Grem1 is strongly up-regulated in patients with coronary artery disease and the Grem1/MIF-ratio correlates significantly with the occurrence of acute plaque rupture. Oral presentation (79. Jahrestagung)

A. Karathanos, K. A. L. Müller, M. Schmid, M. Schneider, M. Chatterjee, M. Gawaz, T. Geisler, I. I. Müller. Macrophage migration inhibitory factor and its endogenous antagonist Gremlin-1 are carried by platelets and the stored

amount of both proteins correlates with the stability of coronary artery disease. Oral presentation (79. Jahrestagung)

M. Droppa, D. Tschernow, K. A. L. Müller, E. Tavlaki, A. Karathanos, F. Stimpfle, M. Gawaz, T. Geisler. Evaluation of clinical risk factors to predict high on-treatment platelet aggregability and outcome in patients with stable coronary artery disease (PREDICT-STABLE). Poster (79. Jahrestagung)

E. Tavlaki, J. Metzger, A. Valera, K. A. L. Müller, A. Karathanos, F. Stimpfle, M. Gawaz, T. Geisler. Variability of on-treatment platelet reactivity under prasugrel and ticagrelor and association with pre-treatment platelet reactivity in a large real-world cohort of ACS patients undergoing PCI. Poster (79. Jahrestagung)

P. Seizer, J. Schwille, A. Karathanos, H. Sturhan, S. v. Ungern Sternberg, O. Borst, T. Geisler, A. May. Extracellular Cyclophilin A activates platelets in vitro and in vivo. Poster (79. Jahrestagung)

K. A. L. Müller, A. Karathanos, S. Breuning, M. Gawaz, T. Geisler, I. I. Müller. Plasma ratio of Gremlin-1 and Macrophage Migration Inhibitory Factor indicates a higher risk for vulnerable plaque formation and acute coronary syndrome in patients with type 2 diabetes mellitus. Poster (79. Jahrestagung)

2014 Clin Res Cardiol 103, Suppl 1 (2014) Impact factor (2014): 4.56

A. Karathanos, K.A.L. Müller, M. Schmid, M. Gawaz, T. Geisler, I.I. Müller. Gremlin-1 is released by platelets and its expression level correlates with the degree of platelet activation in patients with coronary artery disease. Oral presentation (80. Jahrestagung)

M. Haas, A. Karathanos, D. Rath, KAL. Mueller, E. Tavlaki, M. Droppa, F. Stimpfle, II. Mueller, M. Gawaz, T. Geisler. Prognostic impact of platelet macrophage migration inhibitory factor in patients with symptomatic coronary artery disease. Oral presentation (80. Jahrestagung)

I.I. Müller, K.A.L. Müller, A. Karathanos, H. Schönleber, M. Chatterjee, M. Schmid, M. Haas, P. Seizer, H.-F. Langer, M. Gawaz, T. Geisler. Impact of counterbalance between macrophage migration inhibitory factor (MIF) and its endogenous inhibitor Gremlin-1 in patients with symptomatic coronary artery disease. Poster (80. Jahrestagung)

E. Tavlaki, A. Karathanos, M. Droppa, D. Rath, K. A. L. Müller, M. Gawaz, J. Booth, S. Davidson, R. Stables, A. Zaman, W. Banya, M. Flather, M. Dalby, T. Geisler. Benefit of Additional Platelet Inhibition in pre-treated ACS patients with high platelet reactivity undergoing PCI (APACS HPR) – a randomized controlled trial. Poster (80. Jahrestagung)

K.A.L. Müller, A. Karathanos, M. Schmid, M. Gawaz, T. Geisler, I.I. Müller. Plasma ratio of Gremlin-1 and Macrophage Migration Inhibitory Factor indicates a higher risk for plaque instability and acute coronary syndrome in patients with type 2 diabetes mellitus. Poster (80. Jahrestagung)

A. Kiliyas, P. Berlitz, A. Karathanos, K. Rizas, P. Seizer, K. Müller, C. S. Zürn, T. Geisler, M. Gawaz, J. Schreieck. Discontinuation of anticoagulation in patients after “successful” catheter ablation of atrial fibrillation – a study of event-triggered anticoagulation guided by implantable cardiac monitors. Poster (80. Jahrestagung)

I.I. Müller, K.A.L. Müller, A. Karathanos, H. Schönleber, M. Chatterjee, M. Schmid, M. Haas, P. Seizer, H.-F. Langer, M. Gawaz, T. Geisler. Impact of counterbalance between macrophage migration inhibitory factor (MIF) and its endogenous inhibitor Gremlin-1 in patients with symptomatic coronary artery disease. Poster (80. Jahrestagung)

ESC-Jahrestagung:

2013

Geisler T, Müller KA, Karathanos A, Gawaz M, Deliargyris E, Bernstein D, Lincoff AM, Mehran R, Dangas G, Stone G. Short term outcomes of patients undergoing PCI of the left main and correlations with the type of adjunctive antithrombotic therapy: pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trials. Poster

2014

A. Karathanos, K.A.L. Müller, M. Schmid, M. Gawaz, T. Geisler, I.I. Müller. Gremlin-1 is released by platelets and its expression level correlates with the degree of platelet activation in patients with coronary artery disease. European Heart Journal (2014) 35 (Abstract Supplement), 1059. Oral presentation

A. Karathanos, M. Haas, D. Rath, KAL. Mueller, E. Tavlaki, M. Droppa, F. Stimpfle, II. Mueller, M. Gawaz, T. Geisler. Prognostic impact of platelet macrophage migration inhibitory factor in patients with symptomatic coronary artery disease. European Heart Journal (2014) 35 (Abstract Supplement), 486-487. Poster

8. ERKLÄRUNG ZUM EIGENANTEIL DER DISSERTATIONSSCHRIFT

Die Arbeit wurde in der Klinik für Innere Medizin III – Kardiologie und Kreislauferkrankungen unter Betreuung von Herrn Professor Dr. med. T. Geisler durchgeführt.

Die Konzeption der Studie erfolgte durch Herrn Professor Dr. med. T. Geisler.

Die Versuche wurden nach Einarbeitung durch Frau L. Laptev von mir eigenständig durchgeführt.

Die statistische Auswertung erfolgte nach Anleitung durch Herrn Professor Dr. med. T. Geisler durch mich.

Ich versichere, das Manuskript selbständig nach Anleitung durch Herrn Professor Dr. med. T. Geisler verfasst zu haben und keine weiteren als die von mir angegebenen Quellen verwendet zu haben.

Düsseldorf, den 05.12.2016

9. ACKNOWLEDGENTS

Though only my name appears on the cover of this dissertation, a great many people have contributed to its production. My deepest gratitude is to my advisor, Professor Dr. Tobias Geisler. I have been fortunate to have an advisor who gave me the freedom to explore on my own, and at the same time the guidance to recover when my steps faltered. I am deeply grateful to my colleagues and co-advisors Dres. Iris and Karin Müller who helped me with their experience, patience and insightful comments, but also their expertise in the field of MIF and GREM1. I am also indebted to Professor Dr. Gawaz who provided me with the opportunity to understand how much I enjoy research and generously supplied all equipment and expertise to make these experiments possible.

I am so thankful to Ms Laptev and the rest of the lab staff who helped me learn the various lab techniques and maintained all the equipment so efficiently. I am grateful to Ms Lombardi for making the life in the clinic a bit more fun and helping with all the organization and administration without waiting to be asked to.

I am also indebted to all the members of our group who put time to continuing with the experiments, the data acquisition and the recruitment of patients, to confirm the seminal findings of this study, staying late some afternoons after classes or work.

Last but not least, none of that would be possible without the love and encouragement of my family. Their support and care helped me overcome all setbacks and kept me going and to them I dedicate this dissertation.

10. CURRICULUM VITAE

AUSBILDUNG	
9/2004 – 7/2010	Aristoteles-Universität Thessaloniki <i>vorklinischer und klinischer Abschnitt des Medizinstudiums</i> - Abschluss Ärztliche Prüfung, Note: sehr gut - Tutor im klinischen Skills Lab (Okt. 2006-Juni 2007)
BERUFLICHE ERFAHRUNG	
Seit 11. 2014	Universitätsklinikum Düsseldorf <i>Assistenzarzt Klinik für Kardiologie, Pneumologie und Angiologie, Ärztlicher Direktor Univ.-Prof. Dr. med. Malte Kelm</i>
2/2012 – 10/2014	Universitätsklinikum Tübingen <i>Assistenzarzt Innere Medizin III – Kardiologie und Kreislauferkrankungen, Ärztlicher Direktor Univ.-Prof. Dr. Meinrad Paul Gawaz</i>
2/2011 – 1/2012	Universitätsklinikum Tübingen <i>Studienarzt Innere Medizin III – Kardiologie und Kreislauferkrankungen, Ärztlicher Direktor Univ.-Prof. Dr. Meinrad Paul Gawaz</i>
SONSTIGE KENNTNISSE UND QUALIFIKATIONEN	
Sprache	- Griechisch: Muttersprache - Deutsch: Fließend - Englisch: Fließend
EDV-Kenntnisse	- fortgeschrittene Kenntnisse der gängigen Microsoft-Office-Anwendungen - sicherer Umgang mit SPSS - sicherer Umgang mit SAP und Medico (KIS)
Sonstige	- GCP-Training AMG-Studien (8. Februar 2012, CenTrlaL) - Zusatztraining MPG-Studien (3. Dezember 2012, CenTrlaL) - Universität Tübingen Summer course: complementary skills (11.-15. 6. 2012)